

COLLEGE OF MEDICINE CURRICULUM VITAE

Malik E. Juweid, M.D.

American Citizen

Social Security number 022-72-5699

Phone number currently: 00962798515972

I. EDUCATIONAL AND PROFESSIONAL HISTORY

A. List of institutions attended (least to most recent)

1980-1986	University of Heidelberg School of Medicine, Heidelberg, Germany
1986-1989	Clinical Resident, Depts. of Nuclear Medicine and Radiology, Heidelberg University Hospital, German Cancer Research Center, Heidelberg, Germany
1989-1990	Research Fellow, Division of Nuclear Medicine, Massachusetts General Hospital/Harvard Medical School, Boston MA
1990-1991	Research Fellow, Dept. of Nuclear Medicine, the National Institutes of Health, Bethesda MD
1991-1992	Clinical Resident, Division of Nuclear Medicine, Hosp. of the Univ. of Pennsylvania, Philadelphia PA
1992-1993	Research Associate, Nuclear Cardiology Section, Philadelphia Heart Institute, Philadelphia PA

CERTIFICATIONS

9/92, 9/01.10/10	American Board of Nuclear Medicine
June 1992	German Facharzt fur Nuklearmedizin (eligible)
January 1990	Educational Commission for Foreign Medical Graduates (ECFMG Certificate)
September 2011	Jordanian Board of Nuclear Medicine

LICENSURE

December 1992	Commonwealth of Pennsylvania Medical License
April 1993	State of Texas Medical License
July 1993	U.S. Drug Enforcement Agency

April 1994 New Jersey State License

November 2000 Iowa License # 33812

February 2012 Jordanian Medical License

**B. Professional and academic positions held (least to most recent)
(title of position, dates of service, location or institution)**

12/93 – 9/00 Director of Nuclear Medicine and Associate Member
Garden State Cancer Center, Belleville, NJ

7/95 – 7/99 Adjunct Assistant Professor of Radiology, University
of Pennsylvania School of Medicine, Philadelphia,
PA

7/99 -Present Adjunct Associate Professor of Radiology,
University of Pennsylvania School of Medicine,
Philadelphia, PA

10/00 – 6/03 Associate Professor of Radiology, University of Iowa
College of Medicine, Iowa City, IA

7/03 – 6/07 Associate Professor (with tenure) of Radiology,
University of Iowa College of Medicine, Iowa City, IA

7/07 – 1/2012 Professor (with tenure) of Radiology, University of
Iowa College of Medicine, Iowa City, IA

2/09 – 1/2012 Medical Director of Nuclear Medicine, Department of
Radiology, University of Iowa College of Medicine,
Iowa City, IA

2/2012–present Professor of Radiology and Nuclear Medicine,
Department of Radiology, University of Jordan,
Amman, Jordan.

**C. Honors, Awards, Recognitions, Outstanding Achievements (least to
most recent)**

1978 Scholar of German Academic Exchange Agency

1990 Certificate of Merit, Massachusetts General
Hospital, Harvard Medical School

1991 Recognition and Appreciation Award, The National
Institutes of Health

1997 Tatalman Memorial Award, Society of Nuclear
Medicine

2000	Who's Who in America, Science and Engineering
2002	Who's Who in America, Medicine and Healthcare
2005	Donald D. Dorman Research Award, University of Iowa
2007, 2008, 2009	Top 3 Most Viewed Article Published Online In NEJM from 1993-2008

II. TEACHING

- A. Teaching assignments on semester by semester basis (least to most recent)
(classroom, seminar, teaching lab)
(clinical teaching year, weeks/year or hours/week)

October 2000 – June 2001

- Supervision of Nuclear Medicine and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program

July 2001 – June 2002

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2002 – June 2003

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2003 – June 04

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2004 – June 2005

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2005 – June 2006

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2006 – June 2007

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2007 – June 2008

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents

- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2008 – June 2009

Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine

- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2009 – June 2010

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2010 – June 2011

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program
- Didactic lectures for medical students

July 2011– Jan 2012

- Supervision of Nuclear Medicine Residents and Radiology Residents in Nuclear Medicine
- Didactic lectures for Radiology and Nuclear Medicine Residents
- Didactic lectures for students in Nuclear Medicine Technology Program

- Didactic lectures for medical students

Feb 2012 – June 2012

- Didactic lectures for Radiology Residents
- Didactic lectures for medical students

July 2012 – June 2013

- Didactic lectures for Radiology Residents
- Didactic lectures for medical students
- Supervision of Radiology Residents in Nuclear Medicine

July 2013 – June 2014

- Didactic lectures for Radiology Residents
- Didactic lectures for medical students
- Supervision of Radiology Residents in Nuclear Medicine

July 2014 – June 2015

- Didactic lectures for Radiology Residents
- Didactic lectures for medical students

July 2015 – present

- Didactic lectures for Radiology Residents
- Didactic lectures for medical students

**B. Graduate students supervised
(name, degree objective, outcome)**

- Said Saleh, M.D., Hematology/Oncology Fellow, obtained research experience in radioimmunotherapy
- George Hajjar, M.D., Hematology/Oncology Fellow, obtained research experience in radioimmunotherapy

- Megan Blake, M.D., M-4 Medical Student, obtained Nuclear Medicine research experience during 3 week research rotation
- Mustafa Bashir, B.S., M-3 Medical Student, obtained Nuclear Medicine research experience during 3 week research rotation
- Bradley Mullen, M-1 Medical Student, obtained Nuclear Medicine research experience during a summer research fellowship
- Ravinder Chahal, M-1 Medical Student, obtained Nuclear Medicine research experience during a summer research fellowship
- Twyla Bartel, MD, Nuclear Medicine Resident, mentored by me while conducting two Nuclear Medicine research projects
- Jaideep Sohi, MD, Nuclear Medicine Resident, mentored by me while conducting four Nuclear Medicine/PET research projects
- Kim Olsen, MD, Diagnostic Radiology Resident, mentored by me while conducting two PET/CT research projects
- Tony Abraham, DO, Nuclear Medicine Resident, mentored by me while conducting two general Nuclear Medicine and 2 PET/CT research projects
- Saher Sabri, MD, Radiology Resident, mentored by me while conducting a PET/CT research project
- Damita Thomas, MD, Nuclear Medicine Resident, mentored by me while conducting a research project on parathyroid scintigraphy
- Kamaljit Puri, MD, Nuclear Medicine Resident, mentored by me while conducting a research project on adenosine gated-SPECT myocardial perfusion imaging.
- Brianne Seberger, MD, Radiology Resident, mentored by me while conducting a research project on PET/CT in lung cancer.

C. Other contributions to institutional programs
(Institutional conferences, grand rounds, journal clubs)

- Participation and supervision of residents in Weekly Nuclear Medicine Case Conference
- Participation and supervision of residents in Nuclear Medicine Journal Club
- Participation in Weekly Nuclear Medicine Professor Rounds

- Participation in ENT Tumor Board
- Participation in Thoracic Oncology Tumor Board
- Participation in Department of Radiology M&M Conferences

(National education related presentations)

- Radioimmunodetection and Radioimmunotherapy of Medullary Thyroid Cancer. Categorical Seminar, Society of Nuclear Medicine 46th Annual Meeting, Los Angeles, CA, 1999.
- Conventional Radioimmunotherapy of Colorectal (CRC) and Medullary Thyroid Cancer (MTC). Continuing Education Session, Society of Nuclear Medicine 46th Annual Meeting, Los Angeles, CA, 1999.
- Conventional Radioimmunotherapy of Colorectal (CRC) and Medullary Thyroid Cancer (MTC). Continuing Education Session, Society of Nuclear Medicine 46th Annual Meeting, Los Angeles, CA, 1999.
- Anatomy Correlation with Oncology PET Imaging Part 1- Lymphoma. Continuing Education Session, Society of Nuclear Medicine 51st Annual Meeting. Philadelphia, PA, 2004.
- PET in Response Assessment of Cancer. Refresher Course, RSNA, Chicago, IL, 2004.
- PET in Response Assessment of Cancer. Refresher Course, RSNA, Chicago, IL, 2005.
-
- University of Vermont Cancer ASCO Review Course Keynote Speaker, Burlington, VT, 2006.
- PET Scanning in Lymphoma Management. State of the Art Symposium, American Society of Hematology, Las Vegas, NV, 2006.
- PET in Response Assessment of Cancer. Refresher Course, RSNA, Chicago, IL, 2006.
- Radioimmunotherapy of Lymphoma". The 31st Annual *Ted Bloch Memorial Lecture*. Society of Nuclear Medicine Southwestern Chapter Annual Meeting, Little Rock, AK, March 2008.
- Role of PET for Lymphoma Management". Society of Nuclear Medicine Southwestern Chapter Annual Meeting, Little Rock, AK, March 2008.

- Application of targeted imaging to cancer care. At the "Molecular and Translational Oncology Workshop", organized by Cancer Education Consortium (CEC), April, 2008, Reston, VA

(Local and regional CME talks)

"Targeting and treatment of medullary thyroid carcinoma. Current status and future perspectives". Joint Program of Nuclear Medicine. Harvard Medical School, Boston, MA, 1995.

- "Imaging and treatment of hematologic malignancies and solid tumors with radiolabeled antibodies". Monthly Philadelphia Nuclear Medicine Conference, Philadelphia, PA, 1996.

"Radioimmunotherapy of medullary thyroid cancer with radiolabeled antibodies". Weekly Multidisciplinary Conference of Endocrine Neoplasia. M.D. Anderson Cancer Center. Houston, Texas, 1998.

"Radioimmunodetection and radioimmunotherapy of medullary thyroid cancer". Weekly Nuclear Medicine Conference Memorial Sloan Kettering Cancer Center. New York City, New York, 1998.

-
- "Radioimmunotherapy of B-Cell NHL: From Clinical Trials to Clinical Practice". Iowa Radiological Society Meeting, Iowa City, Iowa, 2002.
- "Radioimmunotherapy of B-Cell NHL: From Clinical Trials to Clinical Practice". Missouri Valley Chapter of the Society of Nuclear Medicine, Kansas City, Missouri, 2002.
- "Functional Imaging Lymphoma". Missouri Valley Chapter of the Society of Nuclear Medicine, Coralville, Iowa, 2006.

III. SCHOLARSHIP

A. Publications or creative works (least to most recent) (peer-reviewed papers)

1. Abrams M, **Juweid M**, Ten Kate C, Schwarz R, Hauser MM, Gaul FE, Fucello AJ, Rubin RH, Strauss HW, Fischman AJ. Tc-99m human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med, 31:2022-2028, 1990 (*IF=6.662; 463 citations*).
2. **Juweid M**, Fischman AJ, Rubin RH, Baum R, Strauss HW.

Comparison between Tc-99m-labeled monoclonal antigranulocyte antibody and In-111 labeled polyclonal IgG for detection of focal sites of infection in rats. *Nucl Med Commun*, 12:637-644, 1991 (*IF=1.706; 11 citations*).

3. **Juweid M**, Neumann R, Paik C, Perez-Bacete MJ, Sato J, Van Osdol W, Weinstein NJ. The micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence of a binding site barrier. *Cancer Res* 52:5144-5153, 1992 (*IF=7.514; 289 citations*).
4. **Juweid M**, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. Accumulation of immunoglobulin G at focal sites of inflammation. *Eur J Nucl Med*, 19:159-165, 1992 (*IF=4.532; 58 citations*).
5. Yaoita H, Fischman AJ, Wilkinson R, Khaw BA, **Juweid M**, Strauss HW. Distribution of deoxyglucose and Technetium-99m-glucarate in the acutely ischemic myocardium. *J Nucl Med*, 34:1303-1308, 1993 (*IF=6.662; 25 citations*).
6. Kim CK, Tse KKM, **Juweid M**, Mozly PD, Woda A, Alavi A. Cholescintigraphy in the diagnosis of acute cholecystitis. Morphine-augmentation is superior to delayed imaging. *J Nucl Med*, 34:1866-1870, 1993 (*IF=6.662; 38 citations*).
7. Iskandrian AM, **Juweid M**, Hoe J. The role of nuclear cardiac imaging in ischemic heart disease. *Curr Opinion Cardiol*, 8:562-571, 1993 (*not cited*).
8. Kim CK, **Juweid M**, Woda A, Alavi A. Morphine-augmented versus delayed scintigraphy for the diagnosis of acute cholecystitis. *J Nucl Med*, 34:506-509, 1993 (*IF=6.662; 15 citations*).
9. **Juweid M**, Richards C, Heyman S. Unilateral medullary sponge kidney detected on bone scan. *Clin Nucl Med*, 18:73-74, 1993 (*IF=3.181; 2 citations*).
10. **Juweid M**, Sato J, Paik C, Onay-Basaran S, Weinstein J, Neumann R. A simple method for affinity purification of radiolabeled monoclonal antibodies. *J Nucl Med Biol*, 20:311-315, 1993 (*IF=2.419; 1 citation*).
11. **Juweid M**, Kim CK, Heyman S. Nephrotic syndrome as an unusual paraneoplastic syndrome of Hodgkin's disease demonstrated on Gallium-67 scan. *Clin Nucl Med*, 19:224-227, 1994 (*IF=3.181; 3 citations*).
12. Behr T, Sharkey RM, **Juweid M**, Blumenthal RD, Dunn RM, Griffiths GL, Bair HJ, Wolf FG, Becker WS, Goldenberg DM. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. *Cancer Res*, 55:3825-3834, 1995 (*IF=7.514; 177 citations*).

13. Sharkey RM, **Juweid M**, Shevitz J, Behr T, Dunn R, Swayne LC, Wong GY, Blumenthal RD, Griffiths GL, Siegel JA, Leung S, Hansen HJ, Goldenberg DM. Evaluation of a CDR-grafted (Humanized) Anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. *Cancer Res*, 55:5935-5945, 1995 (*IF=7.514; 103 citations*).
14. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Rubin AD, Hanley D, Markovitz A, Siegel J, Goldenberg DM. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with I-131-labeled monoclonal antibodies to carcinoembryonic antigen. *Cancer Res*, 55:5946-5951, 1995 (*IF=7.514; 32 citations*).
15. **Juweid M**, Sharkey RM, Siegel JA, Behr T, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients with Non-Hodgkin's lymphoma (NHL) and diffuse bone marrow uptake. *Cancer Res*, 55:5827-5831, 1995 (*IF=7.514; 37 citations*).
16. **Juweid M**, Sharkey RM, Markowitz A, Behr T, Swayne LC, Hansen HJ, Shevitz J, Leung S, Rubin AD, Herskovic T, Hanley D, Goldenberg DM. Treatment of Non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. *Cancer Res*, 55:5899-5907, 1995 (*IF=7.514; 143 citations*).
17. Knapp FF, Mirzadeh S, Beets AL, Sharkey R, Griffiths G, **Juweid M**, Goldenberg DM. Curie-scale Tungsten-188/ Rhenium-188 generators for routine clinical applications. *Technetium Chemistry and Nuclear Medicine* 4, 319-384, 1995 (*17 citations*).
18. Behr T, Becker WS Sharkey RM, **Juweid M**, Dunn RM, Bair HJ, Wolf FG, Goldenberg DM. Reduction of renal uptake of 99mTc-labeled monoclonal antibody fragments by amino acid infusion. *J Nucl Med*, 37:829-833, 1996 (*IF=6.662; 87 citations*).
19. Behr T, Sharkey RM, **Juweid M**, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM: Factors influencing pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. *Cancer Res*, 56:1805-1816, 1996 (*IF=7.514; 61 citations*).
20. Behr T, **Juweid M**, Sharkey RM, Swayne LC, Dunn R, and Goldenberg DM. Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumors with I-131-labeled monoclonal antibodies. *Nucl Med Commun*, 17/9:767-780, 1996 (*IF=1.706; 9 citations*).
21. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Dunn R, and Goldenberg DM. Radioimmunotherapy in patients with CEA-producing cancers and small-volume disease using I-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')₂. *J Nucl Med*, 37:1504-1510, 1996 (*IF=6.662; 67 citations*).
22. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Herskovic, Pereira M,

- Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM. Radioimmunotherapy of medullary thyroid carcinoma with I-131-labeled anti-CEA antibodies. *J Nucl Med*, 37:905-911, 1996 (*IF=6.662; 81 citations*).
23. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Dunn R, Ying Z, Siegel J, Hansen HJ and Goldenberg DM. Clinical evaluation of tumor targeting with the anti-CEA murine monoclonal antibody fragment I-131-MN-14 F(ab)₂. *Cancer*, 78:157-168, 1996 (*IF=5.238; 35 citations*).
 24. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic, Hanley D, Markovitz A, Dunn R, Siegel J, Kamal T, Goldenberg DM. Improved detection of medullary thyroid carcinoma with radiolabeled antibodies to carcinoembryonic antigen. *J Clin Oncol*, 14:1209-1217, 1996 (*IF=17.157; 53 citations*).
 25. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths L, Shih LS, Blumenthal RD, Dunn RM, **Juweid M**, and Goldenberg DM. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. *Cancer Immunol Immun*, 44:179-188, 1997 (*IF=3.804; 77 citations*).
 26. Behr T, Sharkey RM, **Juweid M**, Dunn R, Vagg RC, Ying Z, Zhang C-H, Swayne LC, Vardi Y, Siegel J, and Goldenberg DM. Phase I/II clinical radioimmunotherapy with anti-CEA murine monoclonal antibody IgG. *J Nucl Med*, 38:858-870, 1997 (*IF=6.662; 144 citations*).
 27. Blumenthal RD, Alisauskas R, **Juweid M**, Sharkey RM, and Goldenberg DM. Defining the optimal spacing between repeat radioantibody doses in experimental model: is there an accurate measurement of hematopoietic recovery? *Cancer*, 80:2624-2635, 1997 (*IF=5.238; 5 citations*).
 28. Behr T, Sharkey RM, **Juweid M**, Swayne LC, Dunn R, and Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA monoclonal antibodies. *J Nucl Med*, 38:409-418, 1997 (*IF=6.662; 57 citations*).
 29. Dunn RM, **Juweid M**, Sharkey RM, Behr TM, and Goldenberg DM. Can occult metastases be treated by radioimmunotherapy? *Cancer*, 80:2656-2659, 1997 (*IF=5.238; 16 citations*).
 30. Goldenberg DM, **Juweid M**, Dunn RM, and Sharkey RM. Cancer imaging with radiolabeled antibodies: New advances with Tc-99m-labeled monoclonal antibody Fab' fragments, especially CEA-scan, and prospects for therapy. *J Nucl Med Technol*, 25:18-23, 1997 (*not cited*).
 31. **Juweid M**, Dunn R, Sharkey RM, Rubin AD, and Goldenberg DM. Tc-99m-LL1, a potentially new bone marrow imaging agent. *Nucl Med Commun*, 18:142-148, 1997 (*IF=1.706; 4 citations*).
 32. **Juweid M**, Sharkey RM, Swayne LC, Goldenberg DM. Improved

- selection of patients for reoperation after surgery for medullary thyroid cancer (MTC) by imaging with radiolabeled anti-CEA antibodies. *Surgery*, 122:1156-1165, 1997 (*IF*=3.389; 21 citations).
33. **Juweid M**, Zhang CU, Blumenthal RD, Sharkey RM, Dunn R, Dunlop D, Goldenberg DM. Factors influencing hematologic toxicity of radioimmunotherapy with I-131-labeled anti-carcinoembryonic antigen antibodies. *Cancer*, 80:2749-2753, 1997 (*IF*=5.238; 16 citations).
 34. **Juweid M**, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, Goldenberg DM. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with I-131-labeled murine and humanized anti-CEA monoclonal antibodies. *Gynecologic Oncology*, 67:259-271, 1997 (*IF*=2.919; 34 citations).
 35. **Juweid M**, Sharkey RM, Alavi A, Swayne LC, Dunn R, Herskovic T, Hanley D, Rubin AD, Pereira M, and Goldenberg DM. Regression of advanced refractory ovarian cancer treated with I-131-labeled anti-CEA monoclonal antibody. *J Nucl Med*, 38:257-260, 1997 (*IF*=6.662; 27 citations).
 36. Thompson NW, **Juweid M**, Garnaille, et al. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antibodies – *Discussion*. *Surgery*, 122(6):1165, 1997 (not cited).
 37. **Juweid M**, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Siegel J, Goldenberg DM. Pharmacokinetics, dosimetry, and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. *J Nucl Med*, 39:34-42, 1998 (*IF*=6.662; 54 citations).
 38. Behr TM, Sgouros G, Sharkey RM, Dunn RM, Blumenthal RD, Kolbert K, **Juweid M**, Siegel JA, Goldenberg DM. Y-90 dosimetry in nude mouse: evaluation of three dosimetry models in relation to the observed biological effects in radioimmunotherapy (RAIT) of human colon cancer xenografts. *Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, Tennessee*, p 257-271, 1999 (not cited).
 39. Behr TM, Sharkey RM, Dunn RM, **Juweid M**, Siegel JA, Goldenberg DM. Factors influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with I-131-labeled murine and humanized anti-CEA and anti-mucin monoclonal antibodies. *Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, Tennessee*, p 225-239, 1999 (not cited).
 40. Behr TM, Sharkey RM, **Juweid M**, Dunn RM, Vagg RC, Siegel JA, Goldenberg DM. Toxicity in radioimmunotherapy of solid cancers with I-131-labeled anti-CEA NP-4 IgG1: Dependence on red marrow dosimetry and pretreatment. In: *Proceedings of the Sixth International*

- Radiopharmaceutical Dosimetry Symposium, Gatlinburg, Tennessee, p 113-126, 1999 (*not cited*).
41. Dunn RM, **Juweid M**, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. A SPECT-based activity quantification method for dosimetry. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, Tennessee, p 40-47, 1999 (*not cited*).
 42. Stein R, **Juweid M**, Zhang C-H, Goldenberg DM. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer. Clin Cancer Res, 5:3199s-3206s, 1999 (*IF=6.488; 19 citations*).
 43. **Juweid M**, Blumenthal, Lew W, Hajjar G, Goldenberg DM. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor for peripheral blood stem cell harvest. Clin Cancer Res, 5:3337s-3342s, 1999 (*IF=6.488; 7 citations*).
 44. **Juweid M**, Stadmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM. Pharmacokinetics, dosimetry and initial therapeutic results with I-131- and In-111/Y-90 labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res, 5:3292s-3303s, 1999 (*IF=6.488; 141 citations*).
 45. Stein R, **Juweid M**, Mattes MJ, Goldenberg DM. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid cancer. Antibody processing, targeting, and experimental therapy with I-131 and Y-90 labeled MAbs. Cancer Biother Radiopharm, 14:37-47, 1999 (*IF=1.318; 42 citations*).
 46. **Juweid M**, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM. Prediction of hematologic toxicity after radioimmunotherapy with I-131-labeled anti-CEA monoclonal antibodies. J Nucl Med, 40:1609-1616, 1999 (*IF=6.662; 29 citations*).
 47. **Juweid M**, Hajjar G, Swayne LC, Sharkey RM, Suleiman, Herskovic T, Pereira M, Rubin AD, Goldenberg DM. Phase I/II therapy trial of I-31-MN-14 F(ab)₂ anti-CEA monoclonal antibody in patients with metastatic medullary thyroid cancer. Cancer, 85:1828-1842, 1999 (*IF=5.238; 80 citations*).
 48. Tsai DE, Schuster SJ, Matties A, Alavi A, Moore HCF, **Juweid M**, Goldenberg DM, Stadmauer EA. Progressive intermediate-grade non-Hodgkin's lymphoma (NHL) after high-dose chemotherapy and autologous stem cell transplant: changing the natural history with monoclonal antibody therapy. Clin Lymphoma, 1(1):62-66, 2000 (*IF=1.596; 12 citations*).
 49. Blumenthal RD, Lew W, **Juweid M**, Alisaukas R., Zhiliang Y, Goldenberg DM. Plasma FLT3-L levels predict myelorecovery from

- myelosuppressive therapy. *Cancer*, 88:333-343, 2000 (*IF=5.238; 39 citations*).
50. **Juweid M**, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC, Suleiman S, Pereira M, Rubin AD, Goldenberg DM. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using I-131-MN-14 F(ab)₂ anti-CEA monoclonal antibody and autologous hematopoietic stem cell rescue (AHSCR). *J Nucl Med*, 41:93-103, 2000 (*IF=6.662; 79 citations*).
 51. De Nardo GL, **Juweid M**, White CA, Wiseman GA, DeNardo SJ. Role of dosimetry in radioimmunotherapy planning and treatment dosing. *Crit Rev Oncol Hematol*, 39:203-218, 2001 (*IF=4.589; 35 citations*).
 52. Reddy MP, Floresca J, **Juweid M**, Graham MM. Unusual bilaterally symmetrical metastases on bone scan. *Clin Nucl Med*, 27(4):299-301, 2002 (*IF=3.181; 1 citation*).
 53. Reddy MP, Menda Y, Floresca J, **Juweid M**, Graham MM. FDG PET imaging of pseudo-pseudo tumor. *Clin Nucl Med*, 27(6):445-456, 2002 (*IF=3.181; not cited*).
 54. **Juweid ME**, Menda Y, O'Dorisio MS, Bushnell D, Blake M, Madsen M, Johnson J, Graham M. ¹¹¹In-pentetretotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma. *Nucl Med Commun*, 23:983-989, 2002 (*IF=1.706; 7 citations*).
 55. **Juweid M**. Radioimmunotherapy of Non-Hodgkin's lymphoma: from clinical trials to clinical practice. *J Nucl Med*, 43:1507-1529, 2002 (*IF=6.662; 116 citations*).
 56. **Juweid M**. Technology evaluation: Epratuzumab, Immunomedics/Amgen. *Curr Opin Mol Ther*, 5(2):192-198, 2003 (*IF=2.913; 15 citations*).
 57. **Juweid M**, DeNardo GL, Graham M, Vose J. *Editorial* - Radioimmunotherapy: A novel treatment modality for B-cell Non-Hodgkin's lymphoma. *Cancer Biother Radiopharm*, 18(5):673-674, 2003 (*IF=1.318; 8 citations*).
 58. **Juweid M**. *Editorial* Radioimmunotherapy with ¹³¹I-rituximab: what we know and we don't know. *Cancer Biother Radiopharm*, 18:489-495, 2003 (*IF=1.318; 8 citations*).
 59. Bushnell DL, Menda Y, Madsen MT, Link BK, Kahn D, Truhlar SM, **Juweid M**, Shannon M, Murguia JS. ^{99m}Tc Depreotide tumor uptake in patients with Non-Hodgkin's lymphoma. *Nucl Med Commun*, 25(8): 839-843, 2004 (*IF=1.706; 10 citations*).
 60. Bartel T, **Juweid M**, Ponto J, Graham MM. Corn oil emulsion: A simple cholecystagogue for Diagnosis of Chronic Acalculous Cholecystitis. *J*

Nucl Med, 46:67-74, 2005 (*IF=6.662; 20 citations*).

61. Bartel TB, **Juweid M**, O'Dorisio T, Sivitz W, Kirby P. Image in Endocrinology: Scintigraphic detection of benign struma ovarii in a hyperthyroid patient. *J Clin Endocrinol Metab*, 90(6):3771-3772, 2005 (*IF=6.325; 9 citations*).
62. Squires S, **Juweid M**. Visualization of infected cardiac pacemaker leads by SPECT In-111 leukocyte imaging. *Clin Nucl Med*, 30:584-5, 2005 (*IF=3.181; 1 citation*).
63. **Juweid M**, BD Cheson. Role of positron emission tomography in lymphoma *Editorial* -. *J Clin Oncol*, 23:4577-80, 2005 (*IF=17.157; 116 citations*).
64. **Juweid M**, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and ¹⁸F-fluorodeoxyglucose positron emission tomography. *J Clin Oncol*, 23:4652-61, 2005 (*IF=17.157; 324 citations*).
65. **Juweid ME**, Cheson BD. Positron-emission tomography and assessment of cancer therapy. *N Engl J Med*, 354(5):496-507, 2006 (*IF=50.017; 568 citations*).
66. Madsen MT, Bushnell DL, **Juweid ME**, Menda Y, O'Dorisio MS, O'Dorisio T, Besse I. Potential increased tumor dose delivery with combined I311-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretical method. *J Nucl Med*, 47(4):660-667, 2006 (*IF=6.662; 24 citations*).
67. Guerhazi A, **Juweid ME**. Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma. *Br J Radiol*, 79(941):365-367, 2006 (*IF=2.366; 9 citations*).
68. Meyer MA, Aliberti S, Grignani G, Aglietta M, **Juweid ME**, Cheson BD. Positron emission tomography in cancer therapy – Reply. *N Engl J Med*, 354:1959-1960, 2006 (*IF=50.017; 5 citations*).
69. Buck AK, Bommer M, Stilgenbauer S, **Juweid M**, Glatting G, Schirmeister H, Mattfeldt T, Tepsic D, Bunjes D, Mottaghy M, Krause BJ, Naumaier B, Dohner H, Moller P, Reske SN. Molecular imaging of proliferation in malignant lymphoma. *Cancer Res*, 66(22):11055-11061, 2006 (*IF=7.514; 147 citations*).
70. **Juweid M**. Utility of positron emission tomography (PET) in managing patients with Hodgkin's lymphoma. *Am Soc Hematol Educ Program*, 259-265, 2006 (*80 citations*).
71. Kim W, Bartel T, **Juweid M**, Graham MM. Renal cyst uptake following I-131 treatment for thyroid cancer. *Thyroid*, 16(12):1315-1316, 2006 (*IF=3.000; 6*

citations).

- 72. Juweid ME**, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Schneidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Use of positron emission tomography (PET) for response assessment of lymphoma: consensus recommendations of the Imaging Subcommittee of the International Harmonization Project (IHP) in Lymphoma. *J Clin Oncol*, 25(5):571-578, 2007 (*IF=17.157; 1010 citations*).
- 73.** Cheson BD, Pfistner B, **Juweid ME**, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Volker Diehl V. Revised response criteria for malignant lymphoma. *J Clin Oncol*, 25(5):579-586, 2007 (*IF=17.157; 2310 citations*).
- 74.** Kelloff GJ, Sullivan DM, Wilson W, Cheson B, **Juweid M**, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'Connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, Degennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET Lymphoma Demonstration Project Invitational Workshop. *Acad Radiol* 14(3):330-339, 2007 (*IF=2.021; 24 citations*).
- 75.** Buck AK, Kratochwil C, Glatting G, **Juweid M**, Bommer M, Tepsic D, Vogg ATJ, Mattfeldt T, Naumaier B, Moller P, Reske SN. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [F-18]FLT. *Eur J Nucl Med Mol Imaging* 34(11); 1775-1782, 2007 (*IF=4.532; 61 citations*).
- 76. Juweid ME.** Peripheral T-cell lymphomas: variably or routinely fluorodeoxyglucose-avid? Commentary in *Leuk Lymphoma* 48(8):1465-1467, 2007 (*IF=1.939; 1 citation*).
- 77.** Seam P, **Juweid ME**, Cheson BD. The role of FDG-PET scan in patients with lymphoma. *Blood* 110(10):3507-3516, 2007 (*IF=10.432; 237 citations*).
- 78.** Khanna G, O'Dorisio MS, Menda Y, Glasier C, DeYoung BD, Smith BJ, Graham M, **Juweid M**. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. *Pediatr Blood Cancer* 50(3):561-566, 2008 (*IF=0.897; 9 citations*).
- 79. Juweid ME.** 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence? *J Nucl Med* 49(1);9-12, 2008 (*IF=6.662; 31 citations*).
- 80.** Buck AK, Herrmann K, Büschenfelde CM, **Juweid ME**, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN. Imaging bone and soft tissue tumors with the

- proliferation marker [18F]Fluorodeoxythymidine. Clin Cancer Res 14(10):2970-2977, 2008 (*IF=6.488; 51 citations*).
- 81. Juweid ME**, O'Dorisio T, Milhem M. Diagnosis of poorly differentiated thyroid cancer (PDTC) by thyrogen stimulated radioiodine scanning. N Engl J Med 2008; 359:1925-7 (*IF=50.017; 6 citations*).
- 82.** Magner J, **Juweid ME**, O'Dorisio T, Milhem M. Problems associated with the use of Thyrogen in patients with a thyroid gland. N Engl J Med, 359(16):1738-1739, 2008 (*IF=50.017; not cited*).
- 83.** Buck AK, Bommer M, **Juweid ME**, Glatting G, Stilgenbauer S, Mottaghy FM, Schulz M, Kull T, Bunjes D, Möller P, Dohner H, Reske SN. First Demonstration of leukemia imaging with the proliferation marker [18F]Fluorodeoxythymidine. J Nucl Med 49:1756-1762, 2008 (*IF=6.662; 38 citations*).
- 84. Juweid ME**, Weiner G, Link B, Horning SJ, Wiseman G. Measuring granulocyte and monocyte accumulation at malignant lymphoma sites. J Clin Oncol 27: 154-155, 2009 (*IF=17.157; 3 citations*).
- 85.** Besse I, Bushnell D, Madsen M, **Juweid ME**. Modeling combined radiopharmaceutical therapy: a linear optimization framework. Technol Cancer Res Treat 8: 51-60, 2009 (*IF=1.951; 4 citations*).
- 86.** Thomas DL, Bartel T, Menda Y, Howe J, Graham MM, **Juweid ME**. Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing Technetium-99m Sestamibi parathyroid scintigraphy. Clin Nucl Med 34(10):651-655, 2009 (*IF=3.181; 37 citations*).
- 87.** Horning SJ, **Juweid ME**, Schöder H, Wiseman G, McMillan A, Swinnen LJ, Advani R, Gascoyne R, Quon A. Interim positron emission tomography (PET) scans in diffuse large B-cell lymphoma: An independent expert nuclear medicine evaluation of the Eastern Cooperative Group E3404 Study. Blood 115(4):775-777, 2010 (*IF=10.432; 99 citations*).
- 88.** Hayashi D, Lee JC, Devenney-Cakir, Zaim S, Ounadejela S, Solal-Celigny P, **Juweid ME**, Guermazi A. Follicular Non-Hodgkin's Lymphoma (NHL): A Pictorial Review of Multimodality Imaging and Pathological Correlation. Clinical Radiology 65(5):408-420, 2010 (*IF=1.622; 7 citations*).
- 89. Juweid ME**, Vose JM. Imaging in early-stage Hodgkin's lymphoma. N Engl J Med 362: 962, 2010 (*IF=50.017; 4 citations*).
- 90.** Amir G, **Juweid ME**. Nasopharyngeal squamous cell carcinoma metastatic to psoas muscle. Clin Nucl Med 35:545-546, 2010 (*IF=3.181; 3 citations*).
- 91. Juweid ME**, Thomas D, Menda Y, Graham MM, Hermann K, Buck AK, Fayad L. PET/CT imaging with F-18-fluorothymidine (FLT) is unlikely to cause significant hepatorenal or hematologic toxicity. J Nucl Med 51(5):824-

825, 2010 (*IF=6.662; 1 citation*).

- 92. Juweid ME**, Smith B, Itti E, Meignan M. Can the interim FDG-PET standardized uptake value be used to determine the need for residual mass biopsy following dose-dense immunochemotherapy of advanced diffuse large-B-cell lymphoma? *J Clin Oncol* 28 (34):e719-e720, 2010(*IF=17.157; 6 citations*).
- 93.** Hait WN, Khleif SN, Doroshow JH, Gutman SI, Barker PE, Dracopoli NC, Gutierrez A, Skates SJ, Austin MJ, Bast RC Jr, Becker RL, Berry DA, Bradley LA, Bross PF, Chang M, Clark AM, Devanarayan V, Dressler LG, Endres DB, Enns RK, Frullo FJ, Harper CC, Hayes DF, Hinestrosa MC, Hinman L, Hruszkewycz A, Huang PS, Jessup JM, **Juweid ME**, Kalush F, Kaul KL, Kelloff G, Klee GG, Koch WH, Lemery S, Levy JB, Mansfield E, Maurey KM, Moseley GB 3rd, Naples R, Omel JP, Orr MS, Pennello GA, Pignato WJ, Ransohoff DF, Reid LH, Rodriguez H, Schilsky RL, Schueren R, Simon RM, Sluss PM, Sninsky JJ, Srivastava S, Taube SE, Taylor JM, van't Veer LJ, Vishnuvajjala L, Wang SJ, Warrington JA, Watson MS, Weiner RS, Yost J, Rajagopal G, Buetow KH, Tong W, Tucker-Kellogg G, Beck JR, Bryant BM, Crichton D, Kim P, McIntosh MW, O'Leary T, Orr MS, Saltz JH, Shih WJ, Siemers N, Speakman J, Spears P, Srivastava S, Stancampiano BA, Zhang Z, Zujewski J, Compton C, Holloway B, Jewell SD, Mansfield E, Blanchard KL, Cosentino LM, David KA, de Mars M, Dressler LG, Fore IM, Goldman P, Hammond EH, Hegele RG, Juhl HH, Lubensky IA, Miller GA, Mullaney BP, Philip R, Qualman SJ, Rohlfes EM, Sobel ME, Stern HM, Thompson EA, Demetri GD, Dhingra K, Kelloff GJ, Pazdur R, Adelman MJ, Alexander J, Barrett JC, Chang DD, Engel JM, Geoghegan C, Grayzel DS, Grochow LB, Johnston J, Kenkare-Mitra S, Pensak D, Spinella DG, Woollett GR. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. *Clin Cancer Res*. 2010 Jul 1;16(13):3299-318. Epub 2010 May 25 (*IF=6.488; not cited*).
- 94.** Itti E, **Juweid ME**, Haioun C, Yeddes I, Hamza-Maaloul F, El Bez I, Evangelista E., Lin C, Dupuis J, Meignan M. Improvement of early FDG-PET interpretation in diffuse large-B-cell lymphoma: Importance of the reference background. *J Nucl Med* 51:1-6, 2010 (*IF=6.662; 52 citations*).
- 95. Juweid ME**, Mottaghy FM. Current and future aspects of nuclear molecular therapies: a model of theranostics. *Methods*. 2011 Nov;55(3):193-5 (*IF=3.65; 2 citations*).
- 96.** McGuire SM, Menda Y, Ponto LL, Gross B, **Juweid M**, Bayouth JE A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. *Radiother Oncol*. 2011 Apr; 99(1):49-54 (*IF=4.36; 17 citations*).
- 97.** Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, **Juweid ME**, Cheson BD; Cancer and Leukemia Group B. Doxorubicin,

vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. *Blood*. 2011 May 19;117(20):5314-20 (*IF=10.432*; 36 citations).

98. **Juweid ME**. FDG-PET/CT in lymphoma. *Methods Mol Biol*. 2011;727:1-19. Review (*IF=1.29*; not cited).
99. AlSharif A, Akel A, Sheikh Ali R, **Juweid ME**, et al. Is there a correlation between symptoms and bone scintigraphic findings in patients with complex regional pain syndrome? *Ann Nucl Med* 2012, 26(8):665-9 (*IF=1.68*; 2 citations).
100. Hawamdeh ZM, Sheihh-Ali RF, AlSharif A, Otom AH, Ibrahim AI, AlHadidi FA, Samarah OQ, Dheirat IN, **Juweid ME**, et al. The influence of aging on the association between adiposity and bone marrow density in Jordanian postmenopausal women. *J Clin Densitom* 2013,17(1):143-149 (*IF=2.03*; 1 citation).
101. AlSharif AA, Tarawneh ES, Alkawaleet YI, Abukaraky AE, Alahmad HT, Malkawi ZA, **Juweid ME**. Standardization of quantitative single photon emission computed tomography in control individuals and in patients with condylar hyperplasia. *Nucl Med Commun* 2014, 35(12):1268-1276 (*IF=1.67*; 1 citation).
102. Wondergem MJ, Herrmann K, Syrbu S, Zijlstra JM, Hoetjes N, Hoekstra OS, Cillessen SA, Moesbergen LM, Buck AK, Vose JM, **Juweid ME**. F-18 fluorothymidine uptake in follicular lymphoma and error-prone DNA repair. *EJNMMI Res*. 2014 Jan 8;4(1):3. doi: 10.1186/2191-219X-4-3 (2 citations).
103. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, **Juweid M**, Quon A. Prospective multicenter comparison of early interim 18F-FLT PET/CT versus 18F-FDG PET/CT using IHP, EORTC, Deauville, and PERCIST criteria. *Radiology* (*IF=6.867*; in press).

(Chapters)

1. Goldenberg DM, Sharkey RM, Behr TM, and **Juweid M**: Novel clinical applications of CEA in cancer imaging and therapy with radiolabeled antibodies. For "Cell adhesion and communication mediated by the CEA family: basic and clinical perspectives". Ed. Clifford P. Stanners, McGill Cancer Center. Pages 237-266. Published by Harwood Academic Publishers (Amsterdam), 1998.
2. **Juweid M**, Sharkey RM, and Goldenberg DM: Radioimmunotherapy of medullary thyroid carcinoma with I-131-labeled monoclonal antibodies to carcinoembryonic antigen. For "Therapy of malignancies with radioconjugate monoclonal antibodies: present possibilities and future

perspectives" Ed. P. Riva. Pages 231-244. Published by Harwood Academic Publisher gmbh, 1999.

3. **Juweid M**, Sharkey RM, and Goldenberg DM: Radioimmunotherapy of non-Hodgkin's lymphoma with nonmyeloablative doses of monoclonal antibodies. For "Therapy of malignancies with radioconjugate monoclonal antibodies: present possibilities and future perspectives" Ed. P. Riva. P. Riva. Pages 245-262. Published by Harwood Academic Publisher gmbh, 1999.
4. **Juweid M**, and Goldenberg DM: Radiolabeled antibody therapy of medullary cancer of the thyroid" For "Nuclear Oncology" Ed. Drs. Iraj Khalkhali, Jean Maublant and Stanley J. Goldsmith. Pages 245-250, published by Lippincott, Williams & Wilkins, 2000.
5. **Juweid ME**, Scheidehauer C, Buck AK. PET und PET/CT bei malignen lymphomen. In "Nuklearmedizinische Onkologie" Ed. Von Krause, Buck, Schwaiger. Published by Huthig Jehle Rehm GmbH (in German), 2007.
6. **Juweid ME**. PET/CT in Lymphoma. In "PET/CT and Cancer Therapy" Ed. Juweid ME, Hoekstra O. Humana Press, 2011.

(Abstracts)

1. Yaoita H, **Juweid M**, Wilkinson R, Fischman AJ, Strauss HW. Detection of myocardial reperfusion injury with Tc-99m glucarate. J Nucl Med, 31: 795, 1990.
2. Yaoita H, **Juweid M**, Wilkinson R, Fischman AJ, Strauss HW. Relationship of tissue concentration of deoxyglucose and sodium in myocardial infarction. J Nucl Med, 31: 831, 1990.
3. **Juweid M**, Fischman AJ, Abrams M, Rubin RH, Schwartz D, Gaul FE, Hauser, MM, Fucello AJ, Strauss HW. Tc-99m human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal infections in rats. J Nucl Med, 31: 795, 1990.
4. **Juweid M**, Fischman AJ, Rubin RH, Callahan RJ, Khaw BA, Pike MC, Baum R, Strauss HW. Comparison between Tc-99m-labeled monoclonal antibody and in-111 labeled polyclonal IgG for imaging focal infection. J Nucl Med, 31: 813, 1990.
5. **Juweid M**, Moore RH, Fischman AJ, Strauss HW, Rabito CA. Measurement of the glomerular filtration rate with an ambulatory renal monitor. J Nucl Med, 31: 1588, 1990.
6. **Juweid M**, Fischman AJ, Rubin RH, Strauss HW. In-111-labeled proteins in the extravascular compartment of normal muscle. J Nucl Med, 32: 814, 1991.

7. **Juweid M**, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. Accumulation of immunoglobulin G at focal sites of inflammation. *J Nucl Med*, 32: 629, 1991.
8. **Juweid M**, Sato J, Paik C, Onay-Basaran S, Weinstein J, Neumann R. A simple method for affinity purification of labeled monoclonal antibodies. *J Nucl Med*, 32: 628, 1991.
9. Weinstein JN, **Juweid M**, Van Osdol W, Sato J, Fujimori K, Saga T, Heya T, Neumann R. Monoclonal antibody distribution in tumors: theoretical and experimental validation of the "binding-site barrier" hypothesis. *Proc Amer Assoc Cancer Res*, 33: 1992.
10. **Juweid M**, Cartwright, Berlin J, Heyman S. Conservative versus surgical management of antenatal hydronephrosis. *J Nucl Med*, 33: 873, 1992.
11. **Juweid M**, Sato J, Weinstein J, Neumann R. Heterogeneous antibody distribution in solid tumors caused by a binding-site barrier: first direct experimental evidence. *J Nucl Med*, 33: 893, 1992.
12. Kim CK, Tse KM, **Juweid M**, Woda A, Mozley PD, Alavi A. Delayed imaging has an unacceptably low positive predictive value for acute cholecystitis when compared to morphin-augmentation. *J Nucl Med*, 34: 76, 1993.
13. Goldenberg DM, Sharkey RM, Vagg R, **Juweid M**, Swayne L, Udem S, Anton J, Nayyar S, Markowitz A, Conte P, Hansen HJ, Linke MJ, Smulian AG, Walzer PD. Specific antibody targeting and imaging of *Pneumocystis carinii* Pneumonia (PCP) in HIV patients. Presented at the 34th ICAAC meeting 1994.
14. Sharkey RM, Goldenberg DM, Markovitz A, **Juweid M**, Rubin A, Vagg R, Hammerstshaimb L, Shevitz J, Leung S, Shih LB, Mattes MJ, Hansen HJ. Treatment of Non-Hodgkin's lymphoma (NHL) with LL2, an anti-CD22 monoclonal antibody. *J Immunother*, Vol 16, No.2, 160, 1994.
15. Goldenberg DM, Sharkey RM, Vagg R, **Juweid M**, Markowitz AL, Swayne LC, Udem S, Hansen HJ, Walzer PD. Imaging of *Pneumocystis carinii* pneumonia with a ^{99m}Tc-labeled monoclonal antibody fragment. *Eur J Nucl Med*, 21: 800, 1994.
16. Goldenberg DM, Sharkey RM, **Juweid M**, Markowitz AL, Swayne LC, Conte P, Leung SO, Hansen HJ. Initial tumor targeting with ¹³¹I-labeled chimeric LL2 IgG in patients with non-Hodgkin's lymphoma. *Eur J Nucl Med*, 21: 863, 1994.
17. Sharkey RM, **Juweid M**, Behr T, Mattes J, Goldenberg DM. Radio-immunotherapy of Non-Hodgkin's lymphoma with anti-CD22 monoclonal antibody. Presented at the meeting of the Society of Biological Therapy 1994.

18. Sharkey RM, **Juweid M**, Shevitz J, Dunn R, Dunlop D, Vagg R, Leung SO, Griffiths G, Hansen HJ, Goldenberg DM. Preclinical and clinical evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb). *J Immunother*, Vol 16, No.2, 164,1994.
19. **Juweid M**, Sharkey RM, Dunlop D, Dunn R, Siegel JA, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in NHL patients with diffuse bone marrow disease. *J Immunother*, Vol. 16, No 2, 169, 1994.
20. **Juweid M**, Sharkey RM, Rubin A, Behr TM, Dunlop D, Dunn R, Vagg R, Goldenberg DM. Targeting and treatment of medullary thyroid cancer with I-131 labeled murine anti-CEA monoclonal antibodies. *J Immunother*, Vol 16, No. 2, 162, 1994.
21. Goldenberg DM, Sharkey RM, Behr T, **Juweid M**, Mattes MJ, Shih L, Hansen HJ. Radioimmunotherapy (RAIT) of Non-Hodgkin's lymphoma (NHL) with radiolabeled LL2 monoclonal antibody. *Antibody, Immunoconjugates, and Radiopharmaceuticals*, Vol.8, Nr.1, 58, 1995.
22. Goldenberg DM, Sharkey RM, Behr T, **Juweid M**, Mattes MJ, Shih L, Hansen HJ. Radioimmunotherapy (RAIT) of Non-Hodgkin's lymphoma (NHL) with radiolabeled LL2 monoclonal antibody. *Antibody, Immunoconjugates, and Radiopharmaceuticals*, Vol.8, Nr.1, 58, 1995.
23. Behr T, Sharkey RM, Blumenthal RD, **Juweid M**, et al. Reduction of kidney uptake of radiolabeled monoclonal antibody fragments: Preclinical studies and results of a pilot clinical trial. *Eur J Nucl Med*, 22: 765, 1995.
24. Behr T, Sharkey RM, **Juweid M**, et al. Intrazellular retinierte (In-111, Y-88/90) versus freigesetzte (I-131/125) Nuklide in radioimmun-Diagnostic und Therapie von B-Zell-NHL with internalisiertem anti-CD22-Antikörper LL2. *Nucl Med*, 34, A166 (abstract P142), 1995.
25. Behr T, Sharkey RM, **Juweid M**, Swayne LC, Dunn R, and Goldenberg DM. Radioimmunotherapy of CEA-expressing cancers: results of a phase I/II clinical trial. *Eur J Nucl Med*, 22: 818, 1995.
26. Behr T, Sharkey RM, **Juweid M**, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy in radiomunodetection (RAID) and therapy (RAIT) of CEA-expressing tumors. *Eur J Nucl Med*, 22: 816, 1995.
27. Behr T, Sharkey RM, **Juweid M**, et al. Residualizing radiometals (indium, yttrium) versus released (iodine) isotopes in radioimmunodetection and therapy with internalizing antibodies. *Eur J Nucl Med*, 22: 765, 1995.
28. Goldenberg DM, Sharkey RM, **Juweid M**, Behr T, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA)

- monoclonal antibody. *Eur J Nucl Med*, 22: 764, 1995.
29. Behr T, Sharkey RM, **Juweid M**, et al. Influence of antibody protein dose on the dosimetry and diagnostic accuracy in radioimmunodetection (RAID) and therapy (RAIT) of CEA-expressing tumors. *J Nucl Med*, 36: 226,1995.
 30. Behr T, Sharkey RM, **Juweid M**, et al. Residualizing (indium, yttrium) versus released (iodine) isotopes in radioimmunodetection and therapy with internalizing antibodies. *J Nucl Med*, 36: 20, 1995.
 31. Behr T, Sharkey RM, **Juweid M**, et al. Reduction of kidney uptake of radiolabeled antibody (MAB) fragments: Preclinical and clinical results. *J Nucl Med*, Vol 36: 19, 1995.
 32. Behr T, Sharkey RM, **Juweid M**, et al. Reduction des Nierenuptakes Fab'-fragmentierter monoklonaler Antikörper: tierexperimentelle Grundlagen and vorläufige klinische ergebnisse. *Nucl Med*, 34, A96 (abstract V14), 1995.
 33. Behr T, Sharkey RM, **Juweid M**, Swayne LC, Dunn R, and Goldenberg DM. Radioimmunotherapy of CEA-expressing cancers: results of a phase I/II clinical trial. *Eur J Nucl Med*, 22: 818, 1995.
 34. Behr T, Sharkey RM, **Juweid M**, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy in radioimmunodetection (RAID) and therapy (RAIT) of CEA-expressing tumors. *Eur J Nucl Med*, 22: 816, 1995.
 35. Behr T, Sharkey RM, **Juweid M**, et al. Residualizing radiometals (indium, yttrium) versus released (iodine) isotopes in radioimmunodetection and therapy with internalizing antibodies. *Eur J Nucl Med*, 22: 765, 1995.
 36. Goldenberg DM, Sharkey RM, **Juweid M**, Behr T, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody. *Eur J Nucl Med*, 22: 764, 1995.
 37. Behr T, Sharkey RM, **Juweid M**, et al. Influence of antibody protein dose on the dosimetry and diagnostic accuracy in radioimmunodetection (RAID) and therapy (RAIT) of CEA-expressing tumors. *J Nucl Med*, 36: 226, 1995.
 38. Behr T, Sharkey RM, **Juweid M**, et al. Residualizing (indium, yttrium) versus released (iodine) isotopes in radioimmunodetection and therapy with internalizing antibodies. *J Nucl Med*, 36: 20, 1995.
 39. Behr T, Sharkey RM, **Juweid M**, et al. Reduction of kidney uptake of radiolabeled antibody (MAB) fragments: Preclinical and clinical results. *J Nucl Med*, Vol 36: 19, 1995.

40. Behr T, **Juweid M**, Sharkey RM, et al. Einfluss der proteindosis I-131-markierter anti-CEA-Antikörper (IgG, F(ab')₂) auf Tumortargeting und Dosimetrie in Radioimmunodiagnostik- und therapie. Nucl Med, 34, A94 (abstract V8), 1995.
41. Dunn RM, **Juweid M**, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. An automated internal dosimetry scheme for radiolabeled antibodies. Presented at the annual meeting of the AAPM (1995).
42. Sharkey RM, **Juweid M**, Behr T, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody. J Nucl Med, 36: 215, 1995.
43. **Juweid M**, Sharkey RM, Behr T, et al. Chimeric and CDR-grafted humanized LL2 anti-CD 22 monoclonal antibody for imaging and treatment of non-Hodgkin's lymphoma. J Nucl Med, 36: 211, 1995.
44. **Juweid M**, Sharkey RM, Behr T, et al. Targeting and treatment of medullary thyroid carcinoma with radiolabeled monoclonal antibodies against carcinoembryonic antigen. Program/ Proceedings of the American Society of Clinical Oncology, Vol 14, p 422, 1995.
45. Behr T, Sharkey RM, Blumenthal RD, Sgourous G, Dunn RM, Kolbert K, Alisauskus R, **Juweid M**, et al. Improved therapeutic efficacy by overcoming nephrotoxicity in cancer therapy with radiometal-conjugated antibody fragments and peptides. Proceedings of the American Association of Cancer Research, 37:1996.
46. Behr T, Sharkey RM, Dunn R, **Juweid M**, Swayne LC, and Goldenberg DM. Tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with I-131 labeled murine and humanized anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med, 37: 231, 1996.
47. Behr T, Sharkey RM, **Juweid M**, Swayne LC, Dunn R, and Goldenberg DM. Radioimmunotherapy of CEA-expressing cancers: results of a phase I/II with an I-131-labeled anti-CEA monoclonal IgG1. J Nucl Med, 7: 168, 1996.
48. Behr T, Sharkey RM, **Juweid M**, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy in radioimmunodetection and therapy of CEA-expressing tumors. J Nucl Med, 37: 43, 1996.
49. Behr T, Sharkey RM, **Juweid M**, Swayne LC, Dunn R, and Goldenberg DM. Radioimmunotherapy of CEA-expressing cancers: results of a phase I/II with an I-131-labeled murine anti-CEA NP-4 IgG1. Tumor Target, 2(3): 162, 1996.
50. Hansen HJ, Goldenberg DM, **Juweid M**, Sharkey RM, and Mattes MJ. MAb LL1 reacts with MHC-II invariant (Ii) chain on plasma membranes, in

vitro and in vivo. *Tumor Target*, 2(3): 171, 1996.

51. Blumenthal RD, Alisauskas R, **Juweid M**, Sharkey RM, and Goldenberg DM. Defining optimal spacing between repeat radioantibody doses in experimental models: Is there an accurate toxicity endpoint? *Tumor Target*, 2(3): 152, 1996.
52. Dunn R, **Juweid M**, Behr TM, Siegel JA, Sharkey RM, and Goldenberg DM. Regional radioactivity quantification based on SPECT. *J Nucl Med*, 37: 232, 1996.
53. Dunn R, **Juweid M**, Behr TM, Siegel JA, Sharkey RM, and Goldenberg DM. Dosimetric potential of minimal residual disease using radiolabeled antibodies. *J Nucl Med*, 37: 44, 1996.
54. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Dunn R, Rubin A, Herskovic T, Hanley D, and Goldenberg DM. An ongoing phase I study in radio-immunotherapy of advanced refractory ovarian cancer treated with I-131-labeled anti-CEA monoclonal antibody. Program/ Proceedings of the American Society of Clinical Oncology, Vol 15, p 443, 1996.
55. **Juweid M**, Sharkey RM, Dunn R, Hanley D, Herskovic T, Rubin A, Hansen HJ, and Goldenberg DM. Tc-99m-LL1: A potentially new bone marrow imaging agent. *J Nucl Med*, 37: 239, 1996.
56. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Dunn R, and Goldenberg DM. Radioimmunotherapy in patients with CEA-producing cancers and small-volume disease using I-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')₂. *J Nucl Med*, 37: 168, 1996.
57. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Dunn R, Rubin A, Herskovic T, Hanley D, and Goldenberg DM. Radioimmunotherapy of advanced refractory ovarian cancer treated with I-131-labeled anti-CEA MAb: An ongoing phase I study. *J Nucl Med*, 37: 168, 1996.
58. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Dunn R, Ying Z, Siegel J, Hansen HJ, and Goldenberg DM. Clinical evaluation of tumor targeting with the anti-CEA murine monoclonal antibody fragment I-MN-14 F(ab)₂. *J Nucl Med*, 37:169, 1996.
59. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Herskovic, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM. Treatment of medullary thyroid carcinoma with radiolabeled monoclonal antibodies (MAbs) to carcinoembryonic antigen. *J Nucl Med*, 37: 243, 1996.
60. **Juweid M**, Behr TM, Sharkey RM, Swayne LC, Dunn R, Rubin AD, and Goldenberg DM. Factors affecting the relationship between red marrow dose and myelotoxicity in patients receiving radioimmunotherapy with I-131 labeled anti-CEA monoclonal antibodies. *J Nucl Med*, 37: 43, 1996.
61. **Juweid M**, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic,

- Hanley D, Markovitz A, Dunn R, Siegel J, Kamal T, Goldenberg DM. Improved detection of medullary thyroid carcinoma with radiolabeled antibodies to carcinoembryonic antigen. *J Nucl Med*, 37: 9, 1996.
62. **Juweid M**, Zhang C-H, Sharkey RM, Behr TM, Blumenthal RD, Dunn R, Rubin AD, and Goldenberg DM. Factors affecting myelotoxicity in patients receiving radioimmunotherapy with I-131 labeled anti-CEA monoclonal antibodies. *Tumor Target*, 2(3),163, 1996.
63. **Juweid M**, Sharkey RM, Swayne LC, Dunn R, Rubin A, Herskovic T, Hanley D, and Goldenberg DM. Phase I dose-escalation trial of I-131-labeled MN-14 anti-carcinoembryonic antigen (CEA) monoclonal antibody in patient with epithelial ovarian cancer. *Tumor Target*, 2 (3), 189, 1996.
64. Hansen HJ, Goldenberg DM, Sharkey RM, **Juweid M**, et al. Mab LL1 reacts with the cell-surface invariant chain of HLS-Dr complexes on plasma membranes: In vitro and in vivo results. *FASEB*, 10(6):1222, 1996
65. Blumenthal RD, Alisauskas R, **Juweid M**, Sharkey RM, and Goldenberg DM. Myeloid GR-1 expression as an accurate predictor of myelorecovery in experimental models. *Proc Am Assoc Cancer Res*, 38:599, 1997.
66. Behr TM, **Juweid M**, Sharkey RM. CD-22 as target for radioimmunotherapy of hematological malignancies of B-cell origin (non-Hodgkin's lymphoma, acute lymphatic leukemia and macroglobulinemia. *Europ J Cancer*, 33 (Suppl.); S262, 1997 (Abstr. # 1187).
67. **Juweid M**, Stein R, and Goldenberg DM. An animal model of experimental radioimmunotherapy of human medullary thyroid carcinoma. *Proceedings of the American Association of Cancer Research*, 38:237, 1997.
68. **Juweid M**, Zhang C-H, Blumenthal RD, Sharkey RM, Dunlopp D, Dunn D, and Goldenberg DM. A simple mathematical model for predicting myelotoxicity after radioimmunotherapy with I-131 labeled anti-carcinoembryonic antigen monoclonal antibodies. *Proceedings of the American Society of Clinical Oncology*, 1997.
69. **Juweid M**, Sharkey RM, Swayne LC, Dunn R, and Goldenberg DM. Improved selection of patients for reoperation after primary surgery for medullary thyroid carcinoma (MTC) using radiolabeled anti-CEA antibodies. Presented at the 1997 Annual Meeting of the American Society of Endocrine Surgeons.
70. **Juweid M**, Zhang C-H, Blumenthal RD, Sharkey RM, Dunlopp D, Dunn D, and Goldenberg DM. Prediction of myelotoxicity after radioimmunotherapy with I-131 labeled anti-carcinoembryonic antigen monoclonal antibodies in patients with colorectal cancers. *J Nucl Med*, 38:228-229, 1997.

71. **Juweid M**, Stein R, and Goldenberg DM. An experimental model of radioimmunotherapy of medullary thyroid carcinoma (MTC) with radiolabeled antiCEA MAbs. *J Nucl Med*, 38:267, 1997.
72. **Juweid M**, Sharkey RM, Swayne LC, Petryl L, Dunn R, Rubin A, Herskovic T, and Goldenberg DM. Phase I dose-escalation trial of I-131-MN-14 F(ab)₂ anti-CEA MAb in patients with medullary thyroid cancer. *J Nucl Med*, 38:264, 1997.
73. **Juweid M**, Sharkey RM, Swayne LC, and Goldenberg DM. Improved selection of patients for reoperation after primary surgery for medullary thyroid carcinoma (MTC) using radiolabeled anti-CEA antibodies. *J Nucl Med*, 38:232, 1997.
74. **Juweid M**, Sharkey RM, Swayne LC, Alexander S, Dunn R, Rubin A, Herskovic T, and Goldenberg DM. Phase I high-dose trial of I-131-labeled MN-14 F(ab)₂ anti-CEA MAb combined with autologous bone marrow support in patients with advanced medullary thyroid cancer. *J Nucl Med*, 38:47,1997.
75. Dunn RM, **Juweid M**, Sharkey RM, and Goldenberg DM. Patient specific estimates of red marrow dose result in improved correlation with myelotoxicity. Presented at the 45th Annual Meeting of the Society of Nuclear Medicine (SNM) in Toronto, Canada (June 1998).
76. **Juweid M**, Swayne LC, Sharkey RM, and Goldenberg DM. Radioimmunotherapy of epithelial ovarian cancer with I-131-labeled murine anti-CEA monoclonal antibody. Presented at the Annual Meeting of the American Association for Cancer Research, New Orleans, Louisiana, and (March 1998).
77. **Juweid M**, Bhatnagar A, Sharkey RM, Stadmauer E, Luger S, Burton J, Stein R, Alavi A, and Goldenberg DM. Initial clinical experience with I-131-humanized LL2 anti-CD22 MAb against B-cell malignancies. Presented at the 45th Annual Meeting of the Society of Nuclear Medicine (SNM) in Toronto, Canada (June 1998).
78. Goldenberg DM, Bhatnagar A, Sharkey RM, Stadmauer E, Luger S, Burton J, Stein R, Alavi A, and **Juweid M**. Therapy of Non-Hodgkin's lymphoma (NHL) with CDR-grafted (humanized) Immu-LL2 anti-CD22 MAb. *Proceedings of the American Society of Clinical Oncology*, volume 17, Abst # 96, 1998.
79. **Juweid M**, Sharkey RM, Swayne LC, and Goldenberg DM. Phase I/II therapy of I-131-labeled MN-14 F(ab)₂ anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic medullary thyroid cancer. *Proceedings of the American Society of Clinical Oncology*, volume 17, Abst # 1513, 1998.
80. Blumenthal RD, Alissauskas R, Lew W, **Juweid M**, Goldenberg DM. Predictive markers of recovery from myelosuppressive therapy. *Cancer*

- Biother & Radiopharm, vol 13, No 4, p 308, 1998.
81. Stein R, **Juweid M**, Goldenberg DM. Assessment of optimal dose schedule of combined radioimmunotherapy (RAIT) and chemotherapy for treatment of medullary thyroid cancer (MTC). *Cancer Biother & Radiopharm*, vol 13, No 4, p 323, 1998.
 82. **Juweid M**, Dunn R, Zhang C-H, Blumenthal RD, Sharkey RM, Goldenberg DM. The contribution of whole body radiation to red marrow dose in patients receiving radioimmunotherapy with ¹³¹I-labeled anti-carcinoembryonic antigen monoclonal antibodies. *Cancer Biother & Radiopharm*, vol 13, No 4, p 319, 1998.
 83. **Juweid M**, Sharkey RM, Goldenberg DM. Prediction of myelotoxicity based on red marrow dose (RMD) and body surface area (BSA) in patients with medullary thyroid cancer (MTC) treated with radiolabeled anti-CEA antibodies (MAbs). *Cancer Biother & Radiopharm*, vol 13, No 4, p 321, 1998.
 84. **Juweid M**, Blumenthal RD, Reising AL, Goldenberg DM. The administration of Lugol's or SSKI reduces the radiation absorbed dose to the gastrointestinal tract from ¹³¹I-labeled monoclonal antibodies. *Cancer Biother & Radiopharm*, vol 13, No 4, p 326, 1998.
 85. **Juweid M**, Blumenthal RD, Lew W, Burton J, Rubin A, Krupkin R, Goldenberg DM. Timing of RAIT after granulocyte-colony stimulating factor (G-CSF) for peripheral blood stem cell harvest (PBSC) influences post-radioimmunotherapy (RAIT) white blood cell (WBC) toxicity and recovery. *Cancer Biother & Radiopharm*, vol 13, No 4, p 316, 1998.
 86. **Juweid M**, Hajjar G, Sharkey RM, Goldenberg DM. Comparison of normal organ and tumor dosimetry between ¹³¹I-AND ¹¹¹In/90Y-hLL2 anti-CD22 MAb in patients with B-cell malignancies. *Cancer Biother & Radiopharm*, vol 13, No 4, p 302, 1998.
 87. **Juweid M**, Swayne L, Hajjar G, Sharkey RM, Suleiman S, and Goldenberg DM. Phase-II therapy trial of ¹³¹I-MN-14F(ab)₂ anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb) in patients with metastatic medullary thyroid cancer (MTC). *Cancer Biother & Radiopharm*, vol 13, No 4, p 315, 1998.
 88. **Juweid M**, Blumenthal RD, Gold DM, Hajjar G, Yeldell D, Stein R, and Goldenberg DM. Use of Tc-99m- Sestamibi for imaging and assessment of multidrug resistance (MDR) of medullary thyroid cancer (MTC). *Eur J Nucl Med*, 26:1003, 1999.
 89. Goldenberg DM, Rubin A, Hajjar G, Stein R, Sharkey RM, and **Juweid M**. First clinical results of combined RAIT and chemotherapy in patients with medullary thyroid cancer (MTC). *Eur J Nucl Med*, 26:1212, 1999.
 90. **Juweid M**, Mardirossian G, Petorius H, and Goldenberg DM. A model

for calculating the radiation absorbed dose to the myocardium from radioimmunotherapy (RAIT) with monoclonal antibodies (MAbs). *Eur J Nucl Med*, 26:1049, 1999.

91. **Juweid M**, Yeldell D, Mardirossian G, Sharkey RM, and Goldenberg DM. Advantage of ¹¹¹In/90Y over ¹³¹I with “non-internalizing” monoclonal antibodies (MAbs). *Eur J Nucl Med*, 26:1190, 1999.
92. **Juweid M**, Hajjar G, Suleiman S, Sharkey RM, Rubin A, and Goldenberg DM. Evaluation of chronic toxicity after high-dose radioimmunotherapy with ¹³¹I-labeled monoclonal antibodies (MAbs). *Eur J Nucl Med*, 26:988, 1999.
93. Stein R, **Juweid M**, and Goldenberg DM. Combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer. *Proceedings of AACR*, Volume 40, p 644, 1999.
94. Stein R, **Juweid M**, and Goldenberg DM. Effects of unlabeled anti-CEA on the growth of medullary thyroid cancer xenografts. *Proceedings of AACR*, Volume 40, p 18, 1999.
95. **Juweid M**, Rubin A, Hajjar G, Stein R, Sharkey RM, and Goldenberg DM. Preclinical and clinical findings support concurrent RAIT and chemotherapy in patients with medullary thyroid cancer (MTC). *Proceedings of the American Society of Clinical Oncology*, Vol 18, 407A, 1999.
96. **Juweid M**, Blumenthal RD, Gold DM, Hajjar G, Yeldell D, Stein R, and Goldenberg DM. Use of Tc-99m- Sestamibi for imaging and assessment of multidrug resistance (MDR) of medullary thyroid cancer (MTC). *Program & Abstracts, Endocrine Society’s 81st Annual Meeting*. P2-709, 1999.
97. **Juweid M**, Rubin A, Hajjar G, Stein R, Sharkey RM, and Goldenberg DM. First clinical results of combined RAIT and chemotherapy in patients with medullary thyroid cancer (MTC). *Program & Abstracts, Endocrine Society’s 81st Annual Meeting*. P2-726, 1999.
98. **Juweid M**, Mardirossian G, Yeldell D, and Goldenberg DM. Marrow-to-blood ratio with ¹³¹I- and ¹¹¹In-labeled MAbs. *J Nucl Med*, 40:218, 1999.
99. **Juweid M**, Sparks R, and Goldenberg DM. Radiation absorbed dose to hematopoietic stem cells following re-infusion at 90Y blood level of 0.4 uCi/ml post high-dose RAIT with 90Y labeled IgG MAbs. *J Nucl Med*, 40:65, 1999.
100. **Juweid M**, Rubin A, Hajjar G, Stein R, Sharkey RM, and Goldenberg DM. Combined RAIT and chemotherapy in patients with medullary thyroid cancer (MTC: First clinical results. *Clin Cancer Res*, (Suppl) vol 5, p 3748s, 1999.

101. **Juweid M**, Matthies A, Stadmauer E, et al. Conventional and hematopoietic stem-cell-supported radioimmunotherapy (RAIT) with humanized 90Y-LL2 (90Y-hLL2) anti-CD22 MAb in NHL patients who failed high-dose chemotherapy (HDC). *Blood*, Vol 94, p 174a, 1999.
102. Stein R, **Juweid M**, and Goldenberg DM. Effects of unlabeled anti-CEA on the growth of medullary thyroid cancer xenografts. *Proceedings of AACR*. Volume 40, p 18, 1999.
103. **Juweid M**, Blumenthal RD, Gold DM, Hajjar G, Yeldell D, Stein R, and Goldenberg DM. Use of Tc-99m- Sestamibi for imaging and assessment of multidrug resistance (MDR) of medullary thyroid cancer (MTC). *Program & Abstracts, Endocrine Society's 81st Annual Meeting*. P2-709, 1999.
104. Shuster SL, Stadmauer E, Czuczman M, Matthies A, Porter DL, Lamonica D, Tsai DE, Pourdehand M, Sharkey R, Alavi A, Goldenberg DM, and **Juweid M**. Radioimmunotherapy of relapsed/refractory non-Hodgkin's lymphoma (NHL) with 90Y-labeled humanized LL2 (90Y-hLL2) anti-CD22 monoclonal antibody. *Proceedings of ASCO*, Vol 19, p 40a, 2000.
105. Saleh S, DM Goldenberg, D Gold, Blumenthal RD, D Yeldell D, Stein R, Hajjar G, and **Juweid M**. Utility of Tc-99m- Sestamibi as marker of multidrug resistance (MDR) in patients with metastatic medullary thyroid cancer (MTC). *Proceedings of ASCO*, Vol 19, p 181a, 2000.
106. Stein R, **Juweid M**, and Goldenberg DM. Effect of combined treatment using radioimmunotherapy and multiple drug chemotherapy for treatment of medullary thyroid cancer xenografts. *Proceedings of AACR*, Volume 41, p 410, 2000.
107. **Juweid M**, Gold D, Blumenthal RD, Yeldell D, Stein R, Saleh S, Hajjar G, and Goldenberg DM. Value of Tc-99m- Sestamibi as marker of multidrug resistance (MDR) in patients with metastatic cancer. *Proceedings of AACR*, Volume 41, p 802, 2000.
108. Wessels B, Breitz H, Meredith R, **Juweid M**, Pastor M, Colburn M, and DeNardo G. Bone marrow dosimetry adjustments based on age, gender, and prior therapy. *J Nucl Med*, 41:83P, 2000.
109. **Juweid M**, Mardirossian G, Petorius H, D Yeldell and Goldenberg DM. A model for calculating the radiation absorbed dose (MRAD) from radioimmunotherapy (RAIT) with monoclonal antibodies (MAbs). *J Nucl Med*, 41:238P, 2000.
110. Matthies A, Cortes A, **Juweid ME**, Goldenberg DM, and Alavi A. Comparison of tumor targeting with CD22 MAb scanning and 18FDG-PET in patients with relapsed/refractory NHL. *J Nucl Med*, 41:276P, 2000.

111. **Juweid M**, Matthies A, Shuster S.L, Stadmauer E, et al. Conventional and hematopoietic stem-cell-supported (HSC-supported) radioimmunotherapy of relapsed/refractory non-Hodgkin's lymphoma (NHL) with 90Y-humanized LL2 (90Y-hLL2) anti-CD22 MAb. *J Nucl Med*, 41:31P, 2000.
112. **Juweid M**, Rubin AD, Hajjar G, Stein R, Sharkey RM, and Goldenberg DM. Initial Results of an ongoing trial of combined radioimmunotherapy (RAIT) and chemotherapy (CH) in patients with medullary thyroid cancer (MTC). *J Nucl Med*, 41:54P, 2000.
113. **Juweid M**, Sparks R, and Goldenberg DM. Clinical and Dosimetric Validation of a safe level of whole body 90Y (111 MBQ/m²) for reinfusion of hematopoietic stem cells following high-dose radioimmunotherapy (RAIT) with 90Y-labeled monoclonal antibodies. (MAbs). *J Nucl Med*, 41:79P, 2000.
114. Stein R, **Juweid M**, and Goldenberg DM. Combining radioimmunotherapy and chemotherapy enhances the efficacy of either single modality therapy for treatment of medullary thyroid cancer. *J Nucl Med*, 41:305P, 2000.
115. Govindan SV, Stein R, Goldenberg DM, **Juweid ME**, Hansen HJ, and Griffiths GL. Comparative efficacies of 90Y, 177Lu and residualizing 131I in the radioimmunotherapy (RAIT) of a human lung cancer xenograft. *J Nucl Med*, 41:143P, 2000.
116. Leonard JP, Coleman M, Chadburn A, Sharkey RM, **Juweid M**, Goldenberg DM. Epratuzumab (hLL2), anti-CD22 humanized monoclonal antibody is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell non-Hodgkin's lymphoma (NHL). *Blood*, 96(11):2482, Part 1, 2000.
117. **Juweid M**, Menda Y, Howe J, Graham MM. Double-phase (DP) SPECT has higher sensitivity and accuracy and a similar specificity compared with DP planar Tc-99m-MIBI imaging in the detection of parathyroid adenoma (PA). *Eur J Nucl Med* 29:S170, 2002.
118. **Juweid M**, Wiseman G, Menda Y, Vose J, Link B, Graham MM. FDG-PET in the prediction of progression-free survival at 1 year (1-year PFS) of patients with aggressive non-Hodgkin's lymphoma (NHL) following anthracycline-based first-line chemotherapy. *Eur J Nucl Med* 29:S264, 2002.
119. **Juweid M**, Menda Y, Bushnell D, O'Doriso MS, Blake M, Graham MM. In-111-pentetreotide versus bone scintigraphy (PS and BS) in the detection of bone metastases (BM) of neuroblastoma (NB). *Eur J Nucl Med* 29:S287, 2002.
120. **Juweid M**, Wiseman G, Menda Y, Link B, Graham MM. FDG-PET predicts with high accuracy the 1-year progression-free survival (1-year

- PFS) of patients with aggressive non-Hodgkin's lymphoma (NHL) following anthracycline-based first-line chemotherapy. *J Nucl Med*, 43: 124P, 2002.
121. **Juweid M**, Menda Y, Howe J, Graham MM. Double-phase (DP) planar versus SPECT Tc-99m-MIBI imaging in the detection of parathyroid adenoma (PA) or hyperplasia (PA). *J Nucl Med*, 43: 78P, 2002.
 122. Weyburn T, Wiseman GA, Link BK, Menda Y, Vose JM, Graham MM, **Juweid ME**. FDG-PET predicts the one year progression-free survival (1-year PFS) of patients with diffuse large B-cell lymphoma following anthracycline-based chemotherapy. *Blood*, 100(11):768a, 2002.
 123. Vose J, Wiseman GA, Menda Y, Graham MM, **Juweid M**. Innovative metabolism-based response criteria for non-Hodgkin's lymphoma (NHL). *Proceedings of the American Society of Clinical Oncology*, volume 22, Abst # 505, 2003.
 124. **Juweid M**, Bartel T, Kemp A, Menda Y, Bushnell D, Twaddle J, Graham MM. In-111-pentetreotide scintigraphy in the staging/restaging of neuroblastoma. *Proceedings of the American Society of Clinical Oncology*, volume 22, Abst # 3240, 2003.
 125. Bartel T, **Juweid M**, Menda Y, Howe J, Twaddle J, Graham MM. Accuracy of dual-phase Tc-99m-MIBI (DPMIBI) in determining the appropriateness of unilateral neck dissection prior to first neck exploration in patients with primary hyperparathyroidism. *J Nucl Med*, 44:145P, 2003.
 126. Kemp A, **Juweid M**, Bartel T, Menda Y, Bushnell D, Twaddle J, O'Dorisio MS, Graham MM. In-111-pentetreotide scintigraphy in the staging/restaging of somatostatin-receptor positive pediatric tumors. *J Nucl Med*, 44: 348P, 2003.
 127. Bartel T, **Juweid M**, Ponto J, Graham MM. Clinical experience with oral oil emulsion as a cholecystagogue. *J Nucl Med*, 44: 44P, 2003.
 128. Menda Y, O'Dorisio T, Floresca J, Bushnell DL, **Juweid M**, Graham MM. Detection of primary and recurrent carcinoid tumors with F-18-FDG PET: comparison with In-111-pentetreotide. *J Nucl Med*, 44:72P, 2003.
 129. Menda Y, Hoffman H, Funk G, Smith R, **Juweid M**, Graham MM. Combination of FDG PET predicts treatment failure after first line treatment in patients with advanced head and neck cancer. *J Nucl Med*, 44: 387P, 2003.
 130. Bushnell D, Menda Y, Madsen M, Link B, Truhlar S, Kahn D, **Juweid M**, Shannon M, Graham M. Tc-99m Depreotide tumor uptake in patients with non-Hodgkin's lymphoma. *J Nucl Med*, 44: 420P, 2003.
 131. **Juweid M**, Wiseman GA, Menda Y, Vose J, Graham MM. Innovative

- metabolism-based response criteria for non-Hodgkin's lymphoma (NHL). J Nucl Med, 44:189P, 2003.
132. **Juweid M**, Wiseman GA, Menda Y, Link BK, Graham MM, Vose J. Integrated PET plus CT-based response assessment of aggressive non-Hodgkin's lymphoma. Blood, 102(11):629a, 2003.
 133. **Juweid M**, Menda Y, Ohashi K, Otsuka H, Chahal R, Bartel T, Graham MM. Is leukocyte/marrow (LK/M) scintigraphy alone a reliable approach for assessment of osteomyelitis in the diabetic foot or violated bone? Presented at the Society of Nuclear Medicine Annual Meeting, Philadelphia, PA, June 2004.
 134. **Juweid M**, Wiseman G, Menda Y, Stolpen A, Vose J, Graham MM. Integrated PET+CT-based response classification for non-Hodgkin's (NHL). Presented at the Society of Nuclear Medicine Annual Meeting, Philadelphia, PA, June 2004.
 135. Khanna G, Sato Y, **Juweid M**, kao S, Graham M, O'Dorisio. Evaluation of Pediatric CNS tumors with In-111-pentetreotide scintigraphy. Presented at the Society of Pediatric Radiology Meeting, Savannah, GA, May 2004.
 136. Bartel T, **Juweid M**, Menda Y, Graham M. Percent remaining gastric activity at 120 minutes (120-MIN%RGA) is a better indicator of delayed gastric emptying (GE) in diabetic patients compared with GE half-time (GE T1/2). Presented at the Radiological Society of North America Annual Meeting, Chicago, IL, November-December 2004.
 137. Bartel TB, Menda Y, **Juweid M**, Smith R, Funk G, Hoffman H, et al. Value of FDG-PET in the post-therapy surveillance of squamous head and neck cancer. Presented at the Radiological Society of North America Annual Meeting, Chicago, IL, November-December 2004.
 138. Bartel TB, **Juweid ME**, Cooper C, Graham MM. Is it still justified to use F+20 diuretic renography as the initial technique of choice in infants or children with suspected urinary tract obstruction? Presented at the Radiological Society of North America Annual Meeting, Chicago, IL, November-December 2004.
 139. Bartel TB, Sohi J, **Juweid ME**. Is percent remaining gastric activity at 2 hours (120 min % RGA) just as accurate as percent remaining gastric activity at 4 hours (240 min % RGA) in assessment of delayed gastric emptying? Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 2005.
 140. Bartel T, **Juweid M**, Cooper C, Graham M. F+20 diuretic renography has an unacceptably low positive predictive value and high rate of equivocal results for evaluation of urinary tract obstruction in children. Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 2005.

141. **Juweid M**, Wiseman G, Menda Y, Ritchie J, Mottaghy F, Rohren E, Vose J, Bumstein N, Reske S, Graham MM. Proposed interpretation criteria for posttherapy PET/CT studies in lymphoma. Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 2005.
142. Cheson BD, Pfistner B, **Juweid M**, Specht L, Rosen ST, Gascoyne R, Stroobants S, Diehl V. Revised response criteria for malignant lymphoma from the members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma. *Blood*, 106:Abstract 18, 2005.
143. Weiner G, Wiseman G, Link BK, Wooldridge JE, Ponto J, Graham MM, **Juweid M**. Imaging of peripheral blood mononuclear cells (PBMC) trafficking in patients with non-Hodgkin's lymphoma prior to and following therapy. Presented at the American Society of Hematology Annual Meeting, Atlanta, GA, December 2005.
144. Abraham T, Sohi J, Mohr W, Graham MM, **Juweid ME**. Comprehensive evaluation of various parameters for assessment of delayed gastric emptying of solids. Presented at the Society of Nuclear Medicine Annual Meeting, San Diego, CA, June 2006.
145. **Juweid ME**, Stroobants S, Mottaghy F, Dietlein M, Wiseman GA, Schneidhauer K, Hoekstra OS, Buck A, Naumann R, Cheson BD. Recommendations of the imaging committee of the International Harmonization Project (IHP) for FDG-PET (PET) use in patients with lymphoma. Presented at the Society of Nuclear Medicine Annual Meeting, San Diego, CA, June 2006.
146. Cheson BD, Pfistner B, **Juweid M**, Horning SJ, Coiffier B, Gascoyne RD, Fisher RI, Hagenbeek A, Hoppe RT, Diehl V. Recommendations for revised response criteria for malignant lymphoma. Presented at the American Society of Oncology Annual Meeting, Atlanta, GA, June 2006.
147. Bushnell D, **Juweid ME**, Madsen M, Besse I, O'Dorisio T, Menda Y, O'Dorisio MS. Potential increased tumor-dose delivery with combined of ¹³¹I-MIBG and ⁹⁰Y-DOTATOC in the myeloablative setting for treatment of advanced neuroblastoma. Presented at the Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, September 10-October 4, 2006.
148. Sohi J, Abraham T, Olsen K, **Juweid M**. Standardized qualitative (visual) criteria for FDG-PET assessment of residual masses following lymphoma therapy: initial validation in patients with Hodgkin's lymphoma . Presented at the Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, September 10-October 4, 2006.
149. **Juweid ME**, Wiseman G, Witzig T, Link BK, Wooldridge J, Ponto J, Sohi J, Weiner G. Assessment of peripheral blood mononuclear cell (PBMC) trafficking in patients with non-Hodgkin's lymphoma (NHL) prior to and

following therapy. Presented at the Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, September 10-October 4, 2006.

150. **Juweid M**, Sohi J, Abraham T, Olsen K, Qing F. Qualitative versus semiquantitative comparison of uptake intensity in residual masses with the mediastinal blood pool structures as “reference background tissue” for FDG-PET assessment of residual masses following lymphoma therapy. Presented at the Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, September 10-October 4, 2006.
151. **Juweid M**, Stroobants S, Mottaghy F, Hoekstra O, Guermazi A, Dietlein M, Wiseman G, Scheidhauer K, Buck A, Naumann R, Hicks R, Reske S, Schwaiger M, Diehl V, Cheson B. Recommendations of the imaging committee of the International Harmonization Project (IHP) for FDG-PET use in patients with lymphoma. Presented at the Annual Congress of the European Association of Nuclear Medicine, Athens, Greece, September 10-October 4, 2006.
152. Mohr W, Abraham T, Sohi J, **Juweid M**. Percent residual gastric activity at four hours ([%RGA@4Hrs](#)) after a solid meal cannot be reliably predicted from two-hour data. Presented at the RSNA Annual Meeting, Chicago, IL, November 26-December 1, 2006.
153. Abraham T, Menda Y, O’Dorisio T, Bushnell D, **Juweid M**, Graham M. FDG PET imaging of neuroendocrine tumors. Presented at the RSNA Annual Meeting, Chicago, IL, November 26-December 1, 2006.
154. Olsen K, Sohi J, Abraham T, **Juweid M**. Initial validation of standardized qualitative (visual) criteria for assessment of residual masses (RM) following lymphoma therapy. Presented at the RSNA Annual Meeting, Chicago, IL, November 26-December 1, 2006.
155. Mohr W, Abraham T, **Juweid M**. Percent residual gastric activity at four hours (%RGA@4Hrs) after a solid meal cannot be reliably predicted from 2 hour data. Presented at the Society of Nuclear Medicine Annual Meeting, Washington, DC, June 2-6, 2007.
156. **Juweid ME**, Buck AK, Baranowska-Kortylewicz J. Can radiolabeled thymidine analogs (RTAs) be used as in vivo probes of DNA repair synthesis? Presented at the Society of Nuclear Medicine Annual Meeting, New Orleans, LA, June 14-18, 2008
157. **Juweid ME**, Buck AK, Baranowska-Kortylewicz J. Can Measurement of DNA repair using radiolabeled thymidine analogs: Implications for in Vivo Imaging of DNA repair To be presented at the 2008 Annual Congress of the European Association of Nuclear Medicine. Munich, Germany, October 12-15, 2008
158. **Juweid ME**, Buck AK, Baranowska-Kortylewicz J. Validation of the use radiolabeled thymidine analogs (RTAs) for measurement of DNA repair

synthesis as prerequisite for their utilization as in vivo imaging probes of DNA repair. To be presented at the 2008 World Molecular Imaging Congress, Nice, France, September 10-13, 2008

159. Yarlagada R, Menda Y, Hoffman H, **Juweid ME**, Graham MG. Identification of primary tumor with FDG PET-CT in patients presenting with metastatic neck nodes of squamous cell origin. To be presented at the 2008 World Molecular Imaging Congress, Nice, France, September 10-13, 2008
160. Horning SJ, **Juweid ME**, Schoder H, Wiseman G, McMillan A, Swinnen L, Advani RH, Gascoyne R, Quon A. Interim positron emission tomography (PET) in diffuse large B-cell lymphoma; independent expert nuclear medicine evaluation of E3404. To be presented at the 2008 American Society of Hematology, San Francisco, CA, December, 2008
161. Singh H, **Juweid ME**. Improved performance of F-20 diuretic renography (DR) by quantitative assessment of pre and post void collecting system activity (CSA): Experience of the University of Iowa. Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 13-17, 2009.
162. **Juweid ME**, Buck AK, Mottaghy FM, Ponto LL, Moller P. Disproportional increase in thymidine uptake relative to tumor cell proliferation in indolent NHLs indicates enhanced DNA repair. Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 13-17, 2009.
163. **Juweid ME**, Buck AK, Baranowska-Kotylewicz J. Validation of 18F-fluorothymidine (FLT) as in vivo molecular probe for measurement of tumor DNA repair synthesis. Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 13-17, 2009.
164. Puri K, Graham MM, **Juweid ME**. Marked variability in post-adenosine (Ad) stress LVEF determined by SPECT myocardial perfusion study (MPS) in patients (pts) with low probability of CAD. Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 13-17, 2009.
165. Singh H, Graham MM, **Juweid ME**. Naloxone and sincalide after morphine for evaluating RUQ pain. Presented at the Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 13-17, 2009.
166. Thomas D, Berbaum K, Bushnell D, Graham MM, **Juweid ME**. Reproducibility of International Harmonization Project (IHP)-based interpretations of posttherapy PET/CT in patients with Hodgkin's and aggressive non-Hodgkin's lymphoma. Presented at the 2009 Pan Pacific Lymphoma Conference, Kohala Coast, Hawaii, June 22-26, 2009.
167. Thomas D, Berbaum K, Bushnell D, Graham MM, **Juweid ME**. Reproducibility of International Harmonization Project (IHP)-based interpretations of posttherapy PET/CT in patients with Hodgkin's and

aggressive non-Hodgkin's lymphoma. Presented at the World Molecular Imaging Congress, Montreal, Canada, September 23-26, 2009.

168. **Juweid ME**, Syrbu S, DeYoung B, O'Dorisio S, O'Dorisio T. Discordant expression of proliferating cell nuclear antigen (PCNA) and Ki-67 Antigen in carcinoid and pancreatic neuroendocrine tumors (C&PET) likely indicates enhanced DNA repair. *Pancreas* 39(2):279, 2010.
169. **Juweid M**, Thomas D, Bushnell D, Graham M. Do patients with Hodgkin's lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) with a PET-negative residual mass (RM) have a "slightly" worse prognosis than those without RM? Presented at the Society of Nuclear Medicine Annual Meeting, Salt Lake City, Utah, June 5-9, 2010.
170. Itti E, **Juweid M**, Haioun C, Yeddes I, Hamza F, El Bez I, Lin C, Dupuis J, Evangelista E, Meignan M. Improvement of early FDG-PET interpretation in diffuse large B-cell lymphoma (DLBCL): importance of the reference background. Presented at the Society of Nuclear Medicine Annual Meeting, Salt Lake City, Utah, June 5-9, 2010.
171. **Juweid M**, Syrbu S, Buck A. Error-prone DNA repair underlying somatic hypermutation/class-switch recombination (SHM/CSR) identified as major contributor of 18F-fluorothymidine (FLT) in low-grade follicular lymphoma (FL). Presented at the Society of Nuclear Medicine Annual Meeting, Salt Lake City, Utah, June 5-9, 2010.
172. Thomas D, Berbaum K, Graham M, Bushnell D, **Juweid M**. Does quantitative SUV-based analysis improve reproducibility of interpretation of posttherapy PET-CT scans in Hodgkin's and aggressive non-Hodgkin's lymphoma? Presented at the Society of Nuclear Medicine Annual Meeting, Salt Lake City, Utah, June 5-9, 2010.
173. **Juweid M**, Graham M. Potential advantage of moderate increase in coronary blood flow (CBF) using vasodilators: implications for an optimal dose of regadenoson. Presented at the Society of Nuclear Medicine Annual Meeting, Salt Lake City, Utah, June 5-9, 2010.
174. Racila E, Syrbu S, **Juweid M**. Thymidylate synthase (TS) expression in diffuse large B-cell lymphoma (DLBCL): Identification of a potential therapeutic target.
http://bloodjournal.hematologylibrary.org/misc/ASH_Meeting_Abstracts_Info.dtl , December 2010.
175. **Juweid, M. E.**, A. Darawsheh, H. Al-Makhamreh, R. F. Ali, Z. Al-Omari, S. Chiacchio, and A. A. AlSharif. "Is apical thinning related to obesity?." In *EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING*, vol. 39, pp. S425-S425. 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER, 2012.
176. Tamimi, A. F., A. A. Al-Qudah, S. S. Dahbour, Y. G. Albahou, A. T. Al-Masri, R. M. Tarawneh, A. A. Al-Sharif, **M. E. Juweid**, Abou-E-Rish, DM,

and Q. A. Saleh. "BONE MINERAL DENSITY (BMD) IN REFRACTORY EPILEPSY TREATED WITH EPILEPSY SURGERY OUTCOME." In *EPILEPSIA*, vol. 54, pp. 188-189. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL, 2013.

177. Keu KV, Advani R, Fayad L, Macapinlac H, Meza J, Hankins J, Rodriguez A, Vose J, **Juweid M**, Quon A. Comparison of FLT vs. FDG for early therapy monitoring of diffuse large B-cell lymphoma. Society of Nuclear Medicine 2013 Annual Meeting, Vancouver, BC, Canada, Volume: J NUCL MED MEETING ABSTRACTS 2013; 54: 176.
178. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, **Juweid M**, Quon A. Multicenter study for comparison of FLT and FDG PET/CT for early interim therapy monitoring of diffuse large B-cell lymphoma. Society of Nuclear Medicine 2014 Annual Meeting, St. Louis, Missouri, Volume: J NUCL MED MEETING ABSTRACTS 2014; 55:594.
179. Hawamdeh Z, **Juweid M**, Farah K. Kinesiophobia among Jordanian low back pain patients. *Annals of Physical and Rehabilitation Medicine* 57:e184 · May 2014.
180. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, **Juweid M**, Quon A. Prospective multicenter comparison of early interim 18F-FLT PET/CT versus 18F-FDG PET/CT. Society of Nuclear Medicine 2015 Annual Meeting, Baltimore, MD, Volume:56.

C. Published Reviews of Scholarship

1. Iskandrian AM, **Juweid M**, Hoe J. The role of nuclear cardiac imaging in ischemic heart disease. *Curr Opinion Cardiol*, 8:562-571, 1993.
2. **Juweid M**. Radioimmunotherapy of Non-Hodgkin's lymphoma: from clinical trials to clinical practice. *J Nucl Med*, 43:1507-1529, 2002.
3. **Juweid M**. Technology evaluation: Epratuzumab, Immunomedics/Amgen. *Curr Opin Mol Therap*, 5:192-198, 2003
4. **Juweid M**. Radioimmunotherapy with ¹³¹I-rituximab: what we know and we don't know. *Cancer Biother Radiopharm*, 18(4):489-495, 2003.
5. **Juweid M**, Cheson BD. Positron emission tomography and assessment of cancer therapy. *N Engl J Med*, 354:496-407, 2006.

6. Guerhazi A, **Juweid M.** PET poised to alter current paradigm for response assessment of non-Hodgkin's lymphoma. BJR, 79:365-367, 2006.
7. **Juweid M.** Utility of positron emission tomography (PET) in managing patients with Hodgkin's lymphoma. Am Soc Hematol Educ Program, 259-265, 2006.

D. Grants Received

PRINCIPAL INVESTIGATOR OF GRANTS

Title: Fluorothymidine (FLT) for Therapy Monitoring of DLBCL

Source: 1 R01 NIH grant

Amount of Direct Funds: \$1,300,000

Period of Funding: 2010 – 2014

Principal Investigator: Malik Juweid, MD

Percent of Effort: 2.3 cal mos

Percent of Salary Support: 23%

Title: Imaging effector cell trafficking in rituximab therapy of follicular lymphoma

Source: Dana Foundation

Amount of Direct Funds: \$100,000

Period of Funding: 2008 – 2011

Principal Investigator: Malik Juweid, MD

Percent of Effort: 1.80 cal mos

Percent of Salary Support: 15%

Title: Radioimmunotherapy with anti-CEA antibodies in medullary thyroid carcinoma

Source: (RO3 NIH grant)

Amount of Direct Funds: \$212,000

Period of Funding: 1995 – 1997

Principal Investigator: Malik Juweid, MD

Percent of Effort:

Percent of Salary Support:

Title: Treatment of medullary thyroid cancer with I-131-MN14 F(ab)2 and

ABMT Source: (FDA grant)

Amount of Direct Funds: \$633,244

Period of Funding: 1995 – 1998

Principal Investigator: Malik Juweid, MD

Percent of Effort:

Percent of Salary Support:

Title: Radioimmunotherapy of Non-Hodgkin's lymphoma with LL2 MAb

Source: (RO1 NIH grant)

Amount of Direct Funds: \$856,000

Period of Funding: 1996 - 1999

Principal Investigator: Malik Juweid, MD

Percent of Effort:

Percent of Salary Support:

Title: Radioimmunotherapy of refractory ovarian carcinoma combined with

PBSCR

Source: (RO3 NIH grant)

Amount of Direct Funds: \$212,000

Period of Funding: 1998 – 2000

Principal Investigator: Malik Juweid, MD

Percent of Effort:

Percent of Salary Support:

Title: Radioimmunotherapy of Non-Hodgkin's lymphoma with LL2 MAb

Source: (RO1 NIH grant)

Amount of Direct Funds: \$1,518,784

Period of Funding: 1999 – 2002

Principal Investigator: Malik Juweid, MD

Percent of Effort:

Percent of Salary Support:

Title: Treatment of medullary thyroid cancer with Y-90-hMN14 combined with

doxorubicin and PBSCR

Source: (FDA grant)

Amount of Direct Funds: \$633,244

Period of Funding: 1998 – 2001

Principal Investigator: Malik Juweid, MD

Percent of Effort:

Percent of Salary Support:

Title: Combined Radioimmunotherapy and Chemotherapy for Colon

Cancer Source: (RO3 NIH grant)

Amount of Direct Funds: \$212,000

Period of Funding: 1999 – 2001

Principal Investigator: Malik Juweid, MD

Percent of Effort:

Percent of Salary Support:

CO-INVESTIGATOR OF GRANTS:

Current:

Title: Iowa Imaging Response Assessment Team

Source: NIH (3 P30 CA086862-08S2)

Amount of Direct Funds: \$18,548,629

Period of Funding: 07/14/00 – 06/30/10

Principal Investigator: George Weiner, MD

Percent of Effort: 1.20 call mos

Percent of Salary Support: 10%

Role: Co-Investigator

Title: Immune Response to Monoclonal Antibody Therapy of Non-Hodgkin's

Lymphoma

Source: Leukemia & Lymphoma Society
Amount of Direct Funds: \$166,422
Period of Funding: 10/01/06 – 09/30/09
Principal Investigator: George Weiner, MD
Percent of Effort: 0.36 cal mos
Percent of Salary Support: 3%
Role: Co-Investigator

Previous:

PO-1 Radioimmunotherapy of Cancer (Project Leader on Project 4:
Radioimmunotherapy of medullary thyroid cancer;
Core leader on dosimetry core; Co-Project Leader on Project 3:
Radioimmunotherapy of ovarian cancer; Co-Investigator
on Project 2: Radioimmunotherapy of breast cancer
PI: D. M. Goldenberg

PO-1 Clinical Radioimmunodetection and Radioimmunotherapy in the
Management of Cancer (Co-Investigator on Clinical Project)
PI: D.V. Gold

Improved detection of cancer by a second-antibody (RO1 NIH grant)
PI: R.M. Sharkey

Therapy of NSCLL with combined Chemotherapy and
Radioimmunotherapy (RO3 NIH grant)
PI: Jack D. Burton

Combined Chemo-Immunotherapy of refractory NHL
(Leukemia Society of America)
PI: Jack D. Burton

Experimental Radioimmunotherapy of NSCLC
PI: R. Stein

High-dose Radioimmunotherapy of SCLL with Y-90-hMN-14 anti-CEA
MAb (RO3 NIH grant)
PI: Jack D. Burton

Experimental Radioimmunotherapy of NSCLC
PI: R. Stein

High-Dose Radioimmunotherapy of SCLL with Y-90-hMN-14 anti-CEA
Mab (RO3 NIH Grant)
PI: Jack D. Burton

Title: Radioceptor Guided Surgery Therapy of Neural Crest Tumors
Source: (RO1 NIH Grant)
Amount of Direct Funds: \$2,048,447
Period of Funding: 09/27/00 – 08/31/05
PI: M. Sue O'Doriso, MD
Percent of Effort:

Percent of Salary Support:
Role: Co-Investigator

Title: Academic Public Private Partnership Program
Source: (U56 CA110083, NIH Grant)
Amount of Direct Funds: \$73,750
Period of Funding: 07/01/04 – 06/30/06
Principal Investigator: M. Sue O'Dorisio, MD
Percent of Effort: 0 cal mos
Percent of Salary Support: 0%
Role: Co-Investigator

Title: Lymphoma Specialized Program of Research Excellence (SPORE)
Source: NIH (2 P50 CA097274-06)
Amount of Direct Funds: \$13,632,897
Period of Funding: 09/11/02 – 06/30/07
Principal Investigator: George Wiener, MD
Percent of Effort: 0.60 cal mos
Percent of Salary Support: 5%
Role: PI Project 3): Malik Juweid, MD

Title: 111-In-DTPA-Pentetreotide Imaging for Diagnosis and Post-Therapy Surveillance of Pediatric Central Nervous System Tumors
Source: General Electric / Association of University Radiologists
Amount of Direct Funds: \$140,000
Period of Funding: 07/01/05 – 06/30/07
Principal Investigator: Geetika Khanna, MD
Percent of Effort: 0.24 cal mos
Percent of Salary Support: 2%
Role: Co-Investigator

PRINCIPAL INVESTIGATOR OF CLINICAL TRIALS:

Current:

In Vivo imaging of effector cells in anti-lymphoma monoclonal antibody therapy.

PET imaging of the biodistribution of fluorine-18-fluorothymidine (FLT) in non-Hodgkin's lymphoma.

Phase I Study of fluorine-18-fluorothymidine (FLT) for Prognostication and response assessment of carcinoid and pancreatic endocrine tumors.

Previous:

Detection of CEA-producing carcinoma by diagnostic imaging of Fab' fragments of the anti-CEA antibody Immu-4 labeled with Tc-99m

Detection of breast carcinoma by diagnostic imaging of Fab' fragment of the anti-CEA antibody Immu-4 labeled Tc-99m

Phase I/II Radioimmunotherapy with high-dose I-131-labeled Immu-LL2 in Non-Hodgkin's lymphoma combined with autologous bone marrow transplantation to control myelotoxicity

Tc-99m Labeled anti-B cell lymphoma murine monoclonal antibody LL2 in the staging and evaluation of treatment response in NHL

Enhanced radioantibody clearance by an Anti-Antibody: A phase I clinical trial to determine pharmacokinetics, imaging, and dosimetry.

Phase-I dose escalation clinical trial of I-131-labeled murine Anti-carcinoembryonic antigen (CEA) antibodies in human cancers

A pilot clinical trial of I-131-labeled CDR-grafted (Humanized) Anti-carcinoembryonic antigen (CEA) antibody in the treatment of CEA-producing cancers

A phase I clinical trial of I-131 labeled MN-14 F(ab)₂ anti-carcinoembryonic antigen (CEA) antibody in the treatment of medullary thyroid cancer.

Phase I/II radioimmunotherapy with high-dose I-131-labeled murine MN-14 antibody in medullary thyroid cancer (MTC) combined with autologous bone marrow transplantation to control myelotoxicity.

Phase I radioimmunotherapy of colorectal cancer with anti-carcinoembryonic antigen monoclonal antibody: Treatment with I-131-labeled humanized MN-14 IgG.

Phase I/II radioimmunotherapy of NHL: Treatment with I-131-labeled humanized LL2 IgG anti-CD22 monoclonal antibody.

Phase I/II radioimmunotherapy of NHL: Treatment with Y-90-labeled humanized LL2 IgG anti-CD22 monoclonal antibody.

Phase I/II Radioimmunotherapy with high-dose Y-90-labeled humanized Immu-LL2 in Non-Hodgkin's lymphoma combined with autologous peripheral blood stem cell transplantation.

Phase I/II Radioimmunotherapy with high-dose Y-90-labeled humanized Immu-MN-14 combined with autologous peripheral blood stem cell rescue in patients with gastrointestinal cancers.

Phase I/II Radioimmunotherapy with high-dose Y-90-labeled humanized Immu-MN-14 combined with doxorubicin and autologous peripheral blood stem cell rescue in patients with metastatic medullary thyroid cancer.

Phase I/II Radioimmunotherapy with high-dose Y-90-labeled humanized Immu-MN-14 combined with autologous peripheral blood stem cell rescue in patients with advanced refractory ovarian cancer.

Phase I/II Radioimmunotherapy with non-myeloablative doses of Y-90-labeled humanized Immu-MN-14 in patients with advanced refractory ovarian cancer.

Study chair of the companion imaging protocol CALGB 580601 accompanying CALGB 80302, "A phase II trial of preoperative irinotecan, cisplatin, and radiation in esophageal cancer"

Study chair of the companion imaging protocol CALGB 580603 accompanying CALGB 50303 "Phase III randomized study of R-CHOP v. dose-adjusted EPOCH-R with molecular profiling in untreated de novo diffuse large B-cell lymphoma".

Imaging co-chair, CALGB 50203 protocol "A Phase II trial of doxorubicin, vinblastine, and gemcitabine (AVG) chemotherapy for non-bulky stage I and II Hodgkin's lymphoma".

E. Invited Lectures

1. Targeting and treatment of medullary thyroid carcinoma. Current status and future Perspectives. Joint Program of Nuclear Medicine. Harvard Medical School, Boston, MA, 1995.
2. Imaging and treatment of hematologic malignancies and solid tumors with radiolabeled antibodies. Monthly Philadelphia Nuclear Medicine Conference. Philadelphia, PA, 1996.
3. Radioimmunotherapy of medullary thyroid cancer with radiolabeled antibodies. Weekly Multidisciplinary Conference of Endocrine Neoplasia. M.D. Anderson Cancer Center. Houston, Texas, 1998.
4. Radioimmunodetection and Radioimmunotherapy of medullary thyroid cancer. Weekly Nuclear Medicine Conference Memorial Sloan Kettering Cancer Center. New York City, New York, 1998.
5. Radioimmunotherapy of medullary thyroid and ovarian cancer with radiolabeled antibodies. Annual Meeting of the American College of Nuclear Physicians. Big Island, Hawaii, 1999.
6. Radioimmunodetection and Radioimmunotherapy of medullary thyroid cancer. Categorical Seminar, Society of Nuclear Medicine 46th Annual Meeting. Los Angeles, CA, 1999.
7. Conventional radioimmunotherapy of colorectal (CRC) and medullary thyroid cancer (MTC). Continuing Education Session, Society of Nuclear Medicine 46th Annual Meeting. Los Angeles, CA, 1999.
8. Radioimmunotherapy of B-Cell NHL: From Clinical Trials to Clinical Practice. Iowa Radiological Society Meeting, Iowa City, Iowa, 2002.

9. Radioimmunotherapy of Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice. Presented at the Missouri Valley Chapter of the Society of Nuclear Medicine, Kansas City, Missouri, 2002.
10. Integrated PET+CT-based response assessment of non-Hodgkin's lymphoma. Presented at the 2003 Fall Group Meeting of the Cancer and Leukemia Group B (CALGB), Scottsdale, AZ, 2003.
11. Integrated PET+CT-based response classification of non-Hodgkin's lymphoma. Presented at the 2004 Medical Imaging for Oncology Clinical Trials CBI's West Coast Forum, San Diego, CA, 2004.
12. Anatomy correlation with oncology PET imaging Part 1 – Lymphoma. Continuing Education Session, Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, 2004.
13. PET in response assessment of cancer. Refresher Course, RSNA, Chicago, IL, 2004.
14. PET in late-stage drug development and clinical trials. Presented at a national meeting sponsored by the FDA and Drug Information Agency in Washington, DC, 2005.
15. Report of the Imaging Committee at the International Harmonization Meeting for Trial Parameters in Lymphoma (ESMO, Lymphoma Congress, Lugano, Switzerland, 2005).
16. Functional imaging in lymphoma evaluation. World Oncology Congress, New York, New York, October 2005.
17. PET in lymphoma. International Congress on Hematologic Malignancies, Vancouver, British Columbia, Canada, 2005.
18. Recommendations on standardization issues for lymphoma response criteria with FDG-PET. FDG-PET Lymphoma Workshop, The Leukemia & Lymphoma Society, Bethesda, Maryland, March 2006.
19. PET in response assessment of cancer. King Hussein Cancer Center Lecture Series, Amman, Jordan, May 2006.
20. PET in lymphoma. King Hussein Cancer Center Lecture Series, Amman, Jordan, May 2006.
21. PET in lymphoma: diagnosis and prognosis. University of Vermont Cancer Center, Burlington, VT, June 2006.
22. Role of PET scanning in lymphoma management. American Society of Hematology State-of-the-Art Symposium, Las Vegas, Nevada, September 2006.
23. Functional imaging in lymphoma evaluation. 2nd Annual Oncology Congress, New York, New York, October 2006.

24. Functional imaging of lymphomas. Presented at the Missouri Valley Chapter of the Society of Nuclear Medicine Annual Meeting, Coralville, Iowa, October 2006.
25. Role of PET in response assessment. ASH/ASCO Review Conference, Vermont Cancer Center, Burlington, VT, June 2006.
26. PET in response assessment of cancer. Refresher Course, RSNA, Chicago, IL, 2006.
27. PET in staging and restaging of lung cancer. First King Hussein Cancer Center Thoracic Oncology Congress, Amman, Jordan, March 2007.
28. Role of PET in lymphoma management. 47th Annual Meeting of the Japanese Society of Lymphoreticular Tissue Research, Awaji Island, Japan, 2007.
29. The International Harmonization Criteria. Joint Meeting of SNM/AMI/RSNA, Providence, RI, September 2007.
30. Beyond FDG-PET: FLT-PET for assessment of lymphoma. University of Nebraska Medical Center/Section of Hematology-Oncology, Omaha, NE, August 2007.
31. PET scans as predictors of PFS in DLBCL. ASCO's Novel Therapeutics Development in Lymphoma Workshop, Aspen, CO, September 2007.
32. Beyond FDG-PET: FLT-PET for assessment of lymphoma. Yale University School of Medicine, Department of Radiology, New Haven, CT, February 2008.
33. FDG-PET for management of lymphoma. Department of Nuclear Medicine Technische Universitat Munchen, Munchen, Germany, April 2008.
34. Application of targeted imaging to cancer care. Molecular and Translational Oncology Workshop, organized by Cancer Education Consortium (CEC), Reston, VA, April 2008.
35. Radioimmunotherapy of Lymphoma. The 31st Annual Ted Bloch Memorial Lecture. Society of Nuclear Medicine Southwestern Chapter Annual Meeting, Little Rock, AK, March 2008.
36. Role of PET for Lymphoma Management". Society of Nuclear Medicine Southwestern Chapter Annual Meeting, Little Rock, AK, March 2008.
37. Proposed response criteria for interim PET/CT in lymphoma. 10th International Conference on Malignant Lymphoma, Lugano,

Switzerland, June 2008.

38. Application of molecular imaging to cancer care. Hackensack University Medical Center Grand Rounds, Hackensack, NJ, September 2008.
39. Role of FDG-PET/CT for management of lymphoma. University of Maryland Cancer Center Grand Rounds. Baltimore, MD, October 2008.
40. Role of PET in lymphoma management-Today and Tomorrow- 50th Annual Meeting of the Japanese Society of Lymphoreticular Tissue Research, Nigata, Japan, 2010.
41. Functional Imaging of lymphoma. Today and Tomorrow. American University of Beirut, Beirut, Lebanon, July 2011.
42. PET/CT in lymphoma. IAEA Regional Training Course on Nuclear Oncology for Nuclear Medicine Specialists. Amman, Jordan, September 2013.
43. FLT as marker of Proliferation and DNA repair. IAEA Regional Training Course on Nuclear Oncology for Nuclear Medicine Specialists. Amman, Jordan, September 2013.

Conference presentations

See abstracts

Visiting Professorships

1. King Hussein Cancer Center (KHCC), Amman, Jordan, May 2006.

IV. SERVICE

A. Offices Held in Professional Organizations (least to most recent) (Editorships)

Section Editor, Cancer Imaging in the *Oncologist*

Editorial Board, Journal of Nuclear Medicine

(Review panels)

College of Center for Scientific Review (CSR) Reviewers

Lymphoma Taskforce of the American Joint Commission on Cancer (AJCC)

Co-Chair, CALGB Imaging Committee
CALGB, Imaging Committee Liaison to the Lymphoma Committee
Clinical Oncology Study Section, NCI, NIH
Experimental Immunology Study Section, NCI, NIH
Small Business and Innovations Research Grants, NCI, NIH
Biomedical Imaging and Technology Study Section, NCI, NIH
Medical Imaging Study Section, NCI, NIH
NCI SPORE in Lung, Head and Neck, Lymphoma and Brain Cancers
Special
Emphasis Panel
Cancer Biomarker Collaborative (CBC)
New England Journal of Medicine
Journal of Clinical Oncology
Blood
Cancer
Journal of Nuclear Medicine
Cancer Biotherapy and Radiopharmaceuticals
Leukemia & Lymphoma
European Journal of Nuclear Medicine and Molecular Imaging
American Journal of Roentgenology
Annals of Oncology
Clinical Cancer Research
Lancet Neurology
Lancet Oncology
Radiology
Nuklearmedizin
FDA Orphan Drug Products Grants Reviewer

Department of Energy Grants Program Reviewer

Army Breast Cancer Research Program Grants Reviewer

1999 Society of Nuclear Medicine Scientific Program

2000 Society of Nuclear Medicine Scientific Program

2003 Society of Nuclear Medicine Scientific Program

2006 European Association of Nuclear Society Scientific Program

2010 European Association of Nuclear Society Scientific Program

(Departmental, collegiate or university, and national committees)

June 1993 Tarrant County (TX) Medical Society

June 1993 American College of Nuclear Physicians

July 1992 Society of Nuclear Medicine

April 2000 American Society of Hematology

October 2001 American Society of Clinical Oncology

August 2002 American College of Radiology

October 2002 Cancer and Leukemia Group B (CALGB)

September 2005 AACR-FDA-NCI Think Tank on Clinical Biomarkers

(Departmental, collegiate or university, and national service positions)

October 2001 Interviewer: University of Iowa College of Medicine Admission Committee

2003 Member: Scientific Research Committee, Jordan University Hospital

2005 Member: Advisory Committee for the Office of Scientific Research, Jordan University Hospital